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Induction of mucosal immune responses in the horse
Abstract
The studies described in this thesis concern the examination of the equine mucosal 
immune system and the investigation of the efficacy of mucosal vaccination for 
protection of horses against the common respiratory pathogen, equine influenza virus 
(H3N8).
Stimulation of immune responses at the nasophaymgeal induction site was measured 
by detection and enumeration of circulating antigen-speciflc antibody-secreting cells 
(ASC) in the peripheral blood. Cholera toxin B chain (CTB) given intranasally 
induced CTB-speciflc antibodies in both serum and nasal washes (mucosal effector 
site) which was preceded by the appearence of CTB-speciflc ASC in the peripheral 
blood. This confirmed the fiinction of a local immune system in the respiratory tract 
of the horse, and suggested the existance of a common mucosal immune system in 
horses.
Techniques were developed to measure neutralising antibody in nasal secretions of 
ponies after infection with influenza virus (strain A/equi-2/Sussex 89) and intranasal 
vaccination with inactivated virus and CTB. The vaccination protocol, using 
systemically primed animals, elicited circulating influenza-specific ASCs, serum 
haemagglutination-inhibiting antibodies and nasopharyngeal virus neutralising 
antibodies. Intranasally vaccinated ponies were completely protected from challenge 
infection with influenza virus of the homologous strain. This has been the first 
demonstration of the efficacy of intranasal vaccination using inactivated influenza 
virus in horses.
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Chapter 1
Introduction
1.1 Mucosal Immunity
1.1.1 Introduction
The mucosal epithelium forms the barrier between the external and internal environments. 
Its surface area is enormous, in man it has been estimated at around 400 m^ (McGhee and 
Kiyono, 1993) while the equine lung alone is around 2000 m^ (McGorum, 1995). The 
nature of the mucosal tissues brings them into daily contact with large quantities of 
respired and ingested antigens, including viruses and bacteria. This interface is therefore 
the major route of infection for respiratory and gastrointestinal pathogens. Consequently 
immunological effector mechanisms working at the level of the mucosal surface are very 
important.
Experimental investigations in a wide variety of species, including mouse and man, have 
demonstrated the existence of the common mucosal immune system (CMIS). The CMIS 
functions largely as a seperate entity from the systemic immune system, protecting the 
mucosae from infection using combinations of humoral, mainly dimeric secretory IgA 
(sIgA), and cellular mechanisms, including phagocytic cells and cytotoxic T lymphocytes 
(CTL). The great importance of the CMIS for protection from mucosal pathogens, is 
indicated by the metobolic effort expended in maintaining it. It has been estimated that 
about 75% of all plasma cells in the human body are committed to the production of sIgA 
in mucosal tissues (Phillips-Quagliata and Lamm, 1994), which equates to almost 5 grams 
of antibody production per day (McGhee and Kiyono, 1993).
During the stimulation of a mucosal immune response, antigen is first taken up, processed, 
and presented to T and B lymphocytes at the site of deposition or local lymph nodes (the 
induction site). Lymphocytes become activated within the induction site and migrate
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through the blood to distinct effector sites where they terminally differentiate, under the 
influence of antigen and cytokines, to become antibody producing plasma cells and 
effector T lymphocytes (figure 1.1). Thus an immune response stimulated at one site can 
result in an effector immune response in another, for example vaccination in the gut can 
elicit antibody production in the lung (McGhee and Kiyono, 1993).
1.1.2 Induction sites
The most commonly studied induction site for mucosal immune responses is the gut 
associated lymphoid tissue (GALT). GALT is a general term for lymphoid tissues 
distributed in the intestine, including aggregated lymphoid nodules called Beyer's patches 
(PP's, Griebel and Hein, 1996). These "raised areas" in the intestinal mucosa were first 
described by Johanni Conradi Peyeri in 1677 (Croitoru and Bienenstock, 1994 (figure 
1.1)), although it was not until the mid nineteenth century that they were implicated as a 
lymphoid tissues (Brucke (1851), as cited by Croitoru and Bienenstock, 1994). During the 
1970's PP's were more precisely defined in the rabbit where an enriched population of IgA 
precursors was identified that seeded into other areas of the gut (Craig and Cebra, 1971). 
Cell-migration studies in mice showed that PP's were a source of antigen specific IgA 
producing cells which migrated to other regions of the gut lamina propria (Husband and 
Gowans, 1978).
Specialised antigen transporting cells (M cells) were described as the microfold epithelial 
structures overlying human PP's (Owen and Jones, 1978). The fimction of these M cells is 
to transport antigens, viruses, bacteria and protozoa fi*om the gut lumen to the underlying 
lymphoid cells. The follicle-associated epithelium has specialised structural differences 
compared with the surrounding villus epithelium which allows greater uptake of antigen. 
These include a reduced number o f goblet cells, a much reduced mucus layer, and a lack 
of secretory component expression (poly Ig receptor-see below) and IgA secretion.
Figure 1.1 The Common Mucosal Immune System (CMIS).
Figure 1,1 shows a schematic representation of the induction of a mucosal immune 
response in a Beyer's patch (PP). An antigen in the lumen passes through the mucus (M), is 
taken up by the specialised lymphoepithelium of the PP, and is and is processed and 
presented to B (closed circles) and T (open circles) cells. The stimulated B-lymphocytes 
exit the PP via afferent lymphatics, traffic through the blood, and repopulate distant 
mucosal effector sites. Trafficking B-lymphocytes can be detected using an ELISPOT 
technique. Abbreviations: M, mucus; D, dome; C, cortex; G, germinal centre; MLN, 
mesenteric lymph node; URT, upper respiratory tract; GI, gastrointestinal tract; GU, 
genitourinary tract; SG, secretory glands.
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Within the PP of rabbits, B cells are localised in the dome area and germinal centres 
(Ermak et a l, 1994, Phillips-Quagliata and Lamm, 1994). T cells are present in these 
areas but also in distinct T-cell areas between the follicles. About 80 % of PP T cells are 
CD4 +ve helper T cells, and about 20% are CD8 +ve cytotoxic/suppressor cells (Ermak et 
a l, 1994).
The dome in rabbit PP's, beneath the follicle epithelium, is characterised by CD4 +ve 
helper T cells, dendritic cells, mzicrophages, and IgM +ve B cells (Ermak et a l, 1994, 
Phillips-Quagliata and Lamm, 1994). In other species, such as the mouse and human, PP 
dome areas may contain only very few B cells. CD8 +ve T cells are rare in both GALT 
domes and germinal centres. The germinal centres contain isotype-switched B cells, CD4 
+ve helper cells, follicular dendritic cells and macrophages that are phenotypically distinct 
from those found in the dome area (Ermak et a l, 1994).
Similar mucosal lymphoid follicles are found elsewhere in the CMIS, such as the 
nasopharyngeal associated lymphoid tissue (NALT; Pabst and Tschemig, 1997), the 
bronchae (BALT; Sminia et a l, 1989), and the genitourinary system. The NALT, 
principally the Waldéyer's ring in humans, has great structural and functional similarities 
to GALT. An extensive collection of reviews concerning the structure of NALT, and its 
use in intranasal vaccination strategies, has recently been published (Pabst and Tschemig, 
1997; Brandtzaeg and Haneberg, 1997; Tamura and Kurata, 1997; McDermott and Snider, 
1997; Russell and Wu, 1997; Kyd and Dunkley, 1997; and Staats, 1997). The role of 
NALT in the induction of a secretory immunoglobulin response is supported by the 
finding that tonsillectomy and adenoidectomy patients have reduced amounts of IgA in 
the nasopharynx (Donovan and Soothill, 1973) and peripheral blood (Del Rio-Navarro et 
a l, 1995). The nature of the immunological response by NALT depends on the 
physicochemical state of the antigen to which it is exposed. Soluble antigen is taken up
by epithelial cells and macrophages, and in general, this establishes either tolerance or a 
systemic immune response depending upon the immunological properties of the antigen 
itself. Particulate antigens are either removed by mucocilliary clearance or taken up by M 
cells and reach the NALT, particularly in conditions where the mucocilliary escalator is 
damaged, for example during an infection with respiratory virus..
1.1.3 Effector sites
B Lymphocyte responses
The effector arm of the CMIS is made up of a combination of effector T and natural killer 
(NK) cells, and secretory immunoglobulin, of which IgA dominates. In the upper 
respiratory tract (URT), salivary and mammary glands, gastrointestinal and genitourinary 
systems, IgA is produced locally. It has been calculated that approximately 5 x 10^0 %gA 
producing plasma cells populate the human small intestine, compared with 2.5x1 Ql® in the 
spleen and lymph nodes, making the gut the most important area for antibody production 
in the body.
B cells, once stimulated in the induction sites, GALT or BALT, proliferate and become 
switched to IgA production within the nodule (Jones and Cebra, 1974). They pass into the 
regional lymph node, e.g. mesenteric lymph node, continue to proliferate and mature into 
blast cells capable of migration (Gowans and Knight, 1964). The cells enter the blood 
stream via the efferent lymphatics and selectively locate to the lamina propria (LP) due to 
the interaction of specific "homing antigens" on the surface of the lymphoblasts (Jalkanen 
et al., 1986) and specific receptors, "addressins", on the surfaces of the high endothelial 
venules (Streeter et al., 1988) (see chapter 3). The B cells may locate to specific areas of
the LP, for example in the pig where antibody positive cells are 10 times more numerous 
in the crypts than in any other area in the LP (Vega-Lopez et aL, 1993).
Human IgA occurs as two subclasses (IgAl and IgA2) and may be differentially 
distributed in serum and external secretions. Human serum contains mainly monomeric 
IgAl, whereas dimeric IgAl and IgA2 are found in human secretions (McGhee and 
Kiyono, 1993). The two immunoglobulins share a 95% homology in amino acid sequence, 
however, differences around the hinge region of IgA2 confers an increased resistance to 
proteolytic enzymes (Mestecky and McGhee, 1987). The distribution of IgAl and IgA2 
plasma cells in different human mucosal effector sites suggests that different induction 
sites may contribute differentially in the provision of B cells. For example the LP in the 
URT of humans consists mainly of IgAl producing plasma cells, with very few IgA2 
cells. In contrast IgA2 plasma cells dominate in the LP of the lower intestine. Similarly, if 
B cells from tonsillar lymphoid tissues are stimulated in tissue culture they produce 
mainly IgAl (>95%). Appendix B cells produce both IgAl and IgA2. This suggests that 
stimulation of the CMIS in the URT of humans preferentially populates the URT with 
IgAl producing cells, while stimulation of the PP populates the gut with IgA2 producing 
cells (McGhee and Kiyono, 1993).
The B cell effector sites, the lamina propria of the URT, gut, or genitourinary system, are 
covered by epithelial cells that express the polymeric Ig receptor (pIgR) also known as 
secretory component (figure 1.2). The polymeric immunoglobulins produced in the LP 
bind to the pIgR and are then transported through the epithelial cell and are released into 
the external secetions (Kaetzel et a i, 1991).
Figure 1,2 Secretion of IgA into mucus.
Figure 1.2 shows a schematic representation of the secretion of dimeric IgA from the 
lamina propria (LP), through the epithelium (EP), into the mucus.
1. Synthesis of the secretory component (SC) in the rough endoplasmic reticulum. 
Phosphorylation and glycosylation in the golgi apparatus.
2. Binding of extracellular IgA to form SC-IgA.
3. Endocytosis and transcytosis of SC-IgA complex.
4. Release of SC-IgA and free SC into the lumen.
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T lymphocyte responses
T cells also play a major role in the recovery from mucosal infections and may also 
ameliorate their outcome. In the gut, two populations of T cells can be identified, 
intraepithélial (lEL) and lamina propria (LPL) lymphocytes.
lEL are located in the murine intestinal epithelium, between the enterocytes, separated 
from the gut lumen by tight junctions and from the lamina propria by the basement 
membrane. In man lEL can comprise up to 20 % of the total cells in the epithelium 
(Dobbins et a l, 1986). lEL represent a complex mix of T lymphocytes which are 
distinguished from peripheral T lymphocytes by the differential expression of cell surface 
antigens, which may reflect differences in their fiinction (for review see LeFrancois,
1994). For example while lEL's express T cell receptors (TcR) comprised of both ap  and 
yÔ chains, they express a much larger proportion of yô chains than are found in other 
lymphoid organs (Deusch et ah, 1991). lEL's characteristically exhibit a larger proportion 
of CD8 +ve cells than are found in other T cell types, with up to 80% of TcRyô lEL being 
CD8+ve compared with approximately 25% in the peripheral blood (Jarry et aL, 1990). 
Human and murine yÔ lEL, express CD8 in the homodimeric aa  form rather than the 
more common aP heterodimer.
Studies into the origin of these cells have shown that a large proportion of the yÔ lEL are 
extrathymically derived and maturation can be observed at this site during embryogenesis 
(Carding et a i, 1990; Guy-Grand et aL, 1991). lEL's expressing the ap  TcR are mostly 
thymus dependent (Rocha et aL, 1991). A subset of CD8 a a , TcR aP, however, utilise 
TcR "forbidden" Vp genes not found in peripheral T cells, and therefore may also be 
extrathymically derived (Rocha ct aL, 1991; LeFrancois, 1994).
The majority of human CD3 +ve lEL express CD45RO, indicating that they are memoiy 
or recently activated cells (Halstensen et aL, 1990). This is supported by the observation 
that the proportion of porcine lEL that express IL-2R is greater than that seen in peripheral 
blood (20% compared with 7% respectively; Bailey et aL, 1992). Murine lEL have been 
shown to be directly cytotoxic upon isolation, unlike peripheral CDS +ve T-cells which 
usually require to be stimulated in vitro before acquiring cytotoxic activity. This suggests 
that lEL are activated cells maintained in a state ready to kill potential targets (Guy-Grand 
etaL, \99l).
In the human, approximately 50 % of LP T cells are CD4 +ve (the "helper" phenotype) 
and 35 % express CDS and are of the cytotoxic/suppressor phenotype. The majority of 
these cells appear to be memory cells as they are CD45RO +ve (Zeitz et aL, 1991). There 
is a similar situation in mice where greater than 50 % of all gut LP T cells express CD4 
(Mega et aL, 1991). It has been suggested that the function of human and mouse LPL is to 
provide help for the B cells present in the LP (Kanoffe/ al., 1988; Mega et aL, 1991). T 
cell subsets are spatially segregated within the LP and in the adult porcine gut for 
example, LP CD4 +ve cells are largely restricted to the core of the villus. CDS +ve cells, 
in contrast, line the external margins of the LP core, in contact with the basement 
membrane of the epithelium (Vega-Lopez et aL, 1993).
1.1.4 Antigen uptake and presentation.
There are three major routes for antigen to cross the epithelium, (i) antigen may cross the 
epithelium paracellularly, that is, between the epithelial cells over the tight junctions, (ii) 
antigen may pass intracellularly by means of cell absorption, and (ill) antigen may be 
taken up and actively transported to lymphoid follicles such as BALT or GALT.
M cells are a specialised epithelial cell devoted to the transport of luminal antigens and 
they exhibit short microvilli, apical vesicles and an intracellular vesicle transport system 
(see below. Bye et al., 1984). The PP renews its epithelium every 3-4 days (Smith et al., 
1980) and hence, M cells have to be regularly replenished from the crypts surrounding the 
base of each dome.
M cells in the PP of the rabbit are located close to the tip of the dome, have large pockets 
in their basolateral membrane containing B lymphocytes and CD4 and CD8 double 
negative T cells. Tracer particle experiments have shown selective transport across the M 
cell to these basolateral pockets. A large range of particle sizes may be transported, from 
macromolecular complexes such as ferritin (<10 nm), virus particles and liposomes (20- 
200 nm) and large microspheres (0.5-10 pm). However, there is evidence that smaller 
particles (in the nanometer diameter range) may be more efficiently taken up than those of 
a larger size (in the micrometer diameter range) (Maloy et al., 1994; O’Hagan, D. personal 
communication). Uptake of synthetic particles into M cells is extremely rapid, with 
molecules appearing at the basolateral surface as soon as 30 minutes after introduction 
into the lumen. Large particles (>5 pm) are transported to, and remain within, the 
lymphoid follicle whereas smaller particles (<5 pm) are transported through the PP to 
mesenteric lymph nodes and peripheral lymphoid organs (Ermak et al., 1994).
The role of M cells in processing and presentation of antigen is unclear, although they can 
express MHC class II molecules and possess the lysosomal compartments required for 
processing (Allen et al., 1993). M cells have also been shown to stimulate T cells in vitro 
and secrete the cytokine IL-1 (Pappo and Mahlman, 1993). However, although CD4 +ve T 
cells are not found in close proximity with M cells, CD8 +ve T cells are found in the M 
cell pockets where they could recognise M-cell processed antigen (Ermak et al., 1994;
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Jarry et al., 1990). Other professional antigen presenting cells (APC) such as dendritic 
cells and macrophages extend their processes into the M cell pocket and probably co­
operate with the M cell in antigen processing and lymphocyte stimulation. However, the 
division of labour is unknown (Kato and Owen, 1994).
Dendritic cells (DC) are widely distributed in the normal lung and gastrointestinal tracts 
(Holt et al., 1990 and 1994). These mobile leukocytes are characterised phenotypically by 
long dendritic processes, irregular nuclei, and the small numbers of phagolysosomes. 
Although they do not have a prominent phagolysosomal system, they are actively 
macropinocytic and have numerous endosomes and appropriate lysosomal enzymes. They 
lack the phenotypic markers for mononuclear phagocytes and constitutively express high 
levels of MHC class II (for review see Toews, 1991). DCs are reported to play an 
extremely important role in the induction of immune responses after a respiratory 
infection. Very quickly after the onset of both bacterial and viral infections DCs are 
observed to recruit in large numbers to the site of infection (Me William et al., 1994 and 
1997) and then traffic to local lymph nodes to present the processed antigen to naive T- 
cells (Hamilton-Easton and Eichelberger, 1995).
Lung DCs are excellent accessory cells for naive or primed T cells and are 10 to 100 
times more potent than alveolar macrophages (AM) in inducing T cell proliferation 
(Kradin et a l, 1991; Havenith et a l, 1993; Rochester et a l, 1988 ). DCs are found in 
large numbers in close association with the follicle epithelium and are known to take up 
antigen fi-om the gut and airway lumens. For example, antigen injected into the gut has 
been detected in the afferent lymphatics in association with dendritic cells (Liu and 
Macpherson, 1991). Although these cells were also shown to present this antigen to 
primed T cells, the site of presentation in vivo remains unknown. Xia et al. ( 1995) also 
demonstrated that intra-tracheal administration of hen egg lysozyme (HEL) resulted in
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DCs which were capable of stimulating the proliferation of primed T-cells. These antigen 
presenting DCs were found both in the lung, ftom 3 hours to 7 days after administration, 
and in the regional lymph node from 24 hours after administration. Confirmation that 
DCs could induce T cell priming in vivo was obtained by Havenith et al. (1993) who 
showed that very soon after adoptive transfer into the trachea of rats of in vitro antigen- 
pulsed DCs, antigen specific T cells appeared in the local lymph nodes. This effect could 
be reproduced using adoptive transfer of antigen-pulsed alveolar macrophages (AM) but 
10 times more cells were required to induce the equivalent response.
The important role df DCs as "professional" APCs has been emphasised by the 
observation that they can activate MHC class I restricted, CD8+ve antigen specific CTL in 
vitro even in the absence of CD4+ T-cell help (Inaba et a l, 1987; Boog et a l, 1988).
Macrophages are also present along the entire respiratory tract, including the airway 
lumen, the lamina propria, and the lymphoid follicles. They are efficient phagocytic cells, 
internalise large quantities of foreign antigens and process it for presentation by MHC 
class II molecules on the cell surface. Porcine alveolar macrophages have also been shown 
to express IL-1 and TNF-a (Chitko-McKown et al., 1991). The capacity of AM to activate 
naive lymphocytes appears to be weak (Hance, 1991) and their function has often been 
proposed to be in the inhibition of potentially harmful inflammatory immune responses 
(for review see Holt, 1986), so much so that depletion of AM's in vivo enhances the 
capacity of experimental animals to mount an immune response to inhaled antigens 
(Thepen et al., 1989). This down-regulation of lung T-cell responses seems to function by 
preventing T-cell responsiveness to IL-2, but still permitting T-cell activation and 
cytokine secretion, as measured by up-regulation of IL-2R expression and IL-2 production 
(Upham et al., 1995). The AM-suppressed T-cells become locked in Gq/G] phase, 
through a failure to transduce IL-2 signals leading to phosphorylation of IL-2R-associated
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proteins, and are unable to proliferate upon stimulation with Con A (Strickland et ûL, 
1996).
It is thought that once an inflammatory response is underway within the lung the role of 
the AM may change. Under the influence of inflammatory cytokines and infiltrating 
activated T cells, which AM's are capable of stimulating, AM's may switch from their 
normally suppressive role to one of activation of the immune response (Hance, 1991).
The epithelial cells of the URT also may play a large role in antigen presentation. There is 
evidence for accessory cell function by human MHC class II expressing nasal turbinate 
and bronchial epithelial cells (Kalb et al., 1991). Intestinal epithelial cells are capable of 
activating CD4 +ve T cells (Kaiserlain et al., 1989) but to a lesser extent than CD8 +ve T 
cells (Bland and Warren, 1986). Under most circumstances the “suppressor phenotype” 
would appear to prevail, but in inflammatory conditions CD4+ve cells may be 
preferentially activated (Panja and Mayer, 1991).
1.1.5 Cytokine regulation of the mucosal immune system.
When considering the cytokine regulation of the mucosal immune system it is important 
to remember the distinction between mucosal induction and effector sites. It is often 
convenient to consider cytokine environments in terms of Thl and Th2 as described in 
murine CD4 +ve T cell clones by Mosmann and Coffman (1989). However, it should be 
noted that such clear partitioning has not been observed in “whole T-cell” populations or 
in other species. Further, CD8 +ve T cells, APCs, and M cells also secrete cytokines 
which may complicate interpretation of different cytokine profiles within different 
microcnviroments. Traditionally, Thl cells are associated with cell mediated effector 
mechanisms such as cytotoxic lymphocytes (CTL) and can be characterised by the
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production of INF-y and IL-2. Other cytokines often directly associated with the induction 
of Thl-type immune responses are not produced by T-cells, such as IL-12. In contrast, 
Th2 cells are associated with humoral responses and the secretion of IL-4, IL-5, IL-6 , IL- 
10 and tumour necrosis factor-P(TNF-p).
Induction sites
In the GNUS, the induction of an immune response occurs at the level of the mucosal 
epithelium, which areas might primarily include the mucosae associated lymphoid tissue 
(MALT) excluding the germinal centres, and involves the uptake, processing and 
presentation of antigen to T cells, B-cell stimulation and isotype switching, followed by 
clonal expansion of antigen specific B cells.
APC's are also a major source of cytokines. After antigen uptake, M cells have been 
shown to secrete IL-1, an activator of T cells (Pappo and Mahlman, 1993). Cytokines are 
also pivotal in the induction of an immune response by stimulating traffic of APC's to the 
lymphoid tissues. Interferon-y (IFN-y) has been shown to selectively increase the numbers 
of DCs found in the lung (Kradin et al., 1991). MacPherson and colleagues (1995) 
implicated TNF-a in the migration of DCs from the intestine towards the draining lymph 
nodes, thereby suggesting that TNF-a is important in regulating antigen presentation. Pig 
lung macrophages may also play a role in this regulation by producing TNF-a and IL-1 
upon activation with antigen (Chitko-McKown et al. 1991). Once present in the local 
lymph nodes, the presentation of DC associated antigen is up-regulated by granulocyte 
monocyte colony stimulating factor (GM-CSF, Cumberbatch et al., 1991). Another 
mechanism by which cytokines might enhance antigen presentation is the upregulation of 
MHC class n  expression on epithelial cells by IFN-y (Sleiniger el al., 1989) derived from 
intraepithélial CD8 +ve T cells (Cerf-Bensussan et al., 1984).
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In mice, the induction of IgA B cell responses requires contact with a T cell membrane 
and is IL-4 and transforming growth factor p(TGF-p) dependent. IL-4 and TGF-P promote 
isotype switching to IgA (Husband et al., 1994), whereas this is inhibited by INF-y, 
underlining the importance of separate microenvironments within the CMIS (Hodgkin et 
al., 1991). Subsequent differentiation and proliferation is also cytokine dependent, in that 
IL-5, 6  and 10 induce proliferation and amplify IgA secretion, and is independent of T cell 
contact (Husband et al., 1994). The cells responsible for production of these cytokines in 
PP's can be CD4 -i-ve, expressing IL-2,4,5,6 and INF-y ( Hiroi et al., 1994 and 1995), or 
CDS +ve T cells expressing IL-4, 5,10 and INF-y (Lagoo et al., 1994).
Effector sites
Mucosal effector sites are populated by CD4 -i-ve and CDS +ve T cells as well as large 
numbers of IgA producing plasma cells. As such, there are a large number of cytokine 
requirements to service the different effector functions. This can be partly explained by 
the spatial distribution of cytokine secreting cells. For example, LP cells expressing 
mRNA for INF-y are restricted to the basal regions, whereas IL-4, 5, and 6  are found 
throughout the LP and villi (Husband et al., 1994). It is interesting to note that in this 
study IL-6  mRNA was never found in PP's. Work by Taguchi et al. (1990) showed that 
IL-5 secreting cells outnumbered INF-y secreting cells by 3:1 in the LP whereas the ratio 
in the PP was approximately 1:1. Therefore, they concluded that IgA effector but not IgA 
inductive sites were Th2 dependent. This may be somewhat of an oversimplification given 
that Th2-type cytokines such as IL-4 and TGF-p are required for IgA isotype-switching at 
the induction site. Another illustration of the requirement for spatial segregation of
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cytokine production is demonstrated by INF-y, which although not traditionally associated 
with Th2 type cytokines, is produced by lEL's (Cerf-Bensussan et al., 1984) and is 
required for epithelial cell pig receptor expression (Youngman et al., 1994).
Experiments with IL-4 and IL-6  knockout mice showed the differential requirement for 
these cytokines in the induction and maintainance of IgA responses. IL-4 knockout mice 
were deplete of IgA plasma cells and failed to mount an IgA response to antigens injected 
into the PP (Husband et al., 1994). In IL-6  deficient mice, only small numbers of IgA 
secreting plasma cells were seen in the intestine compared with controls. This translated 
into a reduction in influenza specific IgA responses following inoculation with HA- 
expressing vaccinia virus, whereas normal IgA responses could be restored in these mice 
by infection with a recombinant vaccinia virus also expressing the murine IL-6  gene 
(Ramsay et al., 1994). Recently, Bromander and colleagues (1996) have published 
seemingly contradictory evidence in which IL-6  deficient mice exhibited normal mucosal 
IgA responses against OVA. This dichotomy may be explained by the different forms of 
antigen used in these experiments, or differences in the MHC haplotype of the mouse 
strains.
As in the induction sites, cytokines in the effector sites may be secreted by CD4 +ve or 
CDS 4-ve T cells. For example, freshly isolated CDS +ve lEL secrete cytokines normally 
associated with both Thl and Th2 helper function, including IL-5 and INF-y (Taguchi et 
al., 1991)
1.1.6 Immunology of the equine respiratory tract.
Equine URT architecture has been little investigated, and studies by Mair (19S7 and 19SS) 
form the large part of our knowledge of equine respiratory lymphoid tissues.
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Immunoglobulin producing plasma cells can be readily observed throughout the 
respiratory tract (RT) and specific antibody can be detected in mucosal secretions, for 
example after influenza infection (Hannant et al., 1989). The relative proportion of IgA 
and IgG producing cells varies over the length of the RT. There is a predominance of IgA 
producing cells in the nares (roughly 75 %) which progressivley decreases distally. The 
reverse is true for IgG producing cells with a predominance of IgG producing cells in the 
lower airways. This work was performed on older horses (aged 2-12 years), the situation 
may be different however in younger Thoroughbred horses where IgA may predominate 
along the entire RT (T. Blunden, personal communication).
Well defined lymphoid tissue has been shown throughout the RT of the horse. These 
lymphoid tissues are thought to be part of an adaptive CMIS and can be categorized into 
two histological features. Dense infiltrates of closely packed lymphocytes, plasma cells, 
and small numbers of neutrophils are observed as a cellular cuff around the epithelium and 
are distributed sparsely throughout the RT but extensively in the bronchae and 
bronchioles. Their numbers and size vary between individuals and are often seen in the 
interstitium of the lung commonly associated with blood vessels. Lymphoid follicles, very 
similar to GALT, with a modified epithelium are found in the nasal cavity, nasopharynx, 
around the opening of the auditory tube, in the trachea and occasionally in small bronchi 
(figure 1.3). The follicles are usually solitary in the nasal cavity, around the auditory tube, 
proximal trachea, and in the bronchi, whereas in the nasopharynx and larynx they often 
form multiple aggregated nodular lymphoid tissue.
As in other species, the lung epithelial cell of the horse constitutively expresses MHC 
class II (A.Hamblin, personal communication). In contrast with the surrounding areas, the 
epithelium overlying the dome area is thinner, non-cilliated and contains no goblet cells. 
The basement membrane is infiltrated by large numbers of small lymphocytes forming a
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modified lympho-epithelium. The configuration of the epithelium in association with the 
follicles changes throughout the RT. For example, in the rostral areas of the nasopharynx, 
the epithelium shows a polypoid villus-like fold morphology, whereas in the 
nasopharyngeal tonsil, the nodules are more densely packed to form almost a monolayer 
of lymphoid tissue underlying the surface epithelium.
The dome areas underlying the lympho-epithelium contains small and large lymphocytes 
and a small number of plasma cells. Many nodules, especially in the nasopharynx show a 
large nodule of lymphocytes and macrophages which can be differentiated into a dark 
corona and a lighter-staining germinal centre containing mitotic small and medium 
lymphocytes and macrophages. The parafollicular area outside the nodules contains small 
lymphocytes, plasma cells, aterioles, high endothelial venules (HEV) and lymphatics.
Broncho-alveolar lavage (BAL) fluids from the lung airways contain a large number of 
leucocytes even in the clinically healthy horse (Viel, 1983 and 1995). Approximately 60 
% of these leucocytes are macrophages, and 36 % are lymphocytes (of which 95 % are T 
lymphocytes and 5 % are B lymphocytes). The ratio of CD4:CD8 T-cells in BAL fluids is 
less than or equal to 1 (Kydd et al., 1996) in contrast to the peripheral blood where there is 
a larger proportion of CD4+ ve T cells and the CD4+:CD8+ ratio is approximately 3 
(Lunn et al., 1991 ; Kydd et al., 1996). Small numbers of neutrophils (2.2%), mast cells 
(0.4%), and eosinophils (0.03%) are also found in normal equine BAL fluids (Viel, 1995; 
McGorum et al., 1993; Kydd et al., 1996).
During a respiratory infection the numbers of lung leucocytes may alter dramatically.
BAL samples collected during the course of equine herpes virus 1 (EHVl) infection 
showed evidence of neutrophilia, lymphopacnia with a decline in macrophage numbers on 
day 2
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Figure 1.3 Lymphoid follicles in the equine lung.
1. Bronchus with lymphoid tissue from a clinically normal 12 week old. foal (xl40).
2. Bronchus with lymphoid tissue from a clinically normal 3 year old colt (xl40).
L, lumen; G, germinal centre, C, cartilage.
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post infection. At days 21 and 28 there was a reduction of the CD4:CD8 ratio largely as a 
consequence of an increase in CD8 +ve T lymphocytes (Kydd et al., 1996).
These data indicate that the equine RT is an adaptive immunological organ. The fact that 
there are selectively more CD8+ than CD4+ T cells within the lung compartment and the 
fact that they express lL-2 receptors and show lymphokine activated killer activity (LAK) 
(Kydd et al., 1994), suggests that the lung is a site of dynamic immunological response. It 
possesses the histological apparatus of a common mucosal immune system similar to that 
found in humans and has been shown to respond to infections in terms of BAL cytology 
and local antibody responses. In humans, immunological responses at the level of the RT 
have been shown to be protective for many respiratory pathogens (Clements et al., 1984 
and 1986). The existence of activated immunological responses in the equine RT indicates 
a significant role of these mucosal immunological responses in the protection of the horse 
against pathogenic insult.
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1.2 Aspects of mucosal vaccination
1.2.1 Introduction
The vast mucosal surface in mammals provides the site of infection for the majority of 
respiratory and gastrointestinal pathogens. It is now almost universally accepted that the 
mucosal immune system is best adapted to provide protection from mucosal pathogens 
thanks to the anatomical location of its effector mechanisms at the site of initial infection.
Since the 1970's there has been a concerted effort to investigate the common mucosal 
immune system (CMIS) and to develop effective methods of mucosal vaccination to 
combat mucosal pathogens (Ogra et al., 1980). In general, the induction of sterile 
immunity against mucosal pathogens requires strong effector mechanisms at the level of 
the mucosal surface, these are most effectively achieved by administering immunogens by 
the mucosal route rather than parenterally (Mestecky, 1987).
1.2.2. Importance of mucosal effector responses
The effector arms of the CMIS include humoral (comprising mainly secretory IgA, slgA), 
and cellular responses, including cytotoxic lymphocytes (CTL). There is a great deal of 
experimental evidence that IgA is the most important mediator of protection present at the 
mucosal surface. Passive administration of virus specific IgA into the nares of recipient 
mice is sufficient to protect them from experimental infection with a number of viruses, 
including sendai (Mazanec et a l, 1987) and influenza (Tamura et a l, 1990). Secretory 
IgA, but not monomeric IgG, when injected systemically into mice locates to the mucosal 
surface and protects the upper respiratory tract (URT) from influenza virus infection
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(Renegar and Small, 1991). IgA may also be a major mediator of cross-protection from 
heterologous influenza infection (Liew et al., 1984; Tamura et al., 1990; Asanuma et aU,
1995). This situation has also been implied during human influenza vaccine trials where 
protection from infection is most strongly correlated with nasal HA specific IgA 
(Clements et al., 1984 and 1986).
There have been many roles proposed for sIgA in the protection of the mucosal epithelium 
(Outlaw and Dimmock, 1990 and 1991). These include the creation of a mucosal barrier 
across which specific pathogens cannot pass and prevention of binding to the target cell 
(Lamm, 1976; Taylor and Dimmock, 1985; Mestecky and McGhee, 1987), intracellular 
neutralisation of viral growth during IgA transport (Mazanec et al., 1995), and excretion 
of IgA-antigen complexes formed in the lamina propria after an infection (Kaetzel et al., 
1991, Lamm et al., 1992).
1.2.3. Adjuvants and delivery systems
Unfortunately, simple application of non-replicating antigens onto the mucosal surface 
either orally or intranasally, rarely stimulates significant sIgA responses, and can lead to 
mucosal tolerance through the activation of CD8+ve suppressor T cells (Ke and Kapp,
1996). Thus, wide range of mucosal adjuvants and delivery systems have been developed 
to attempt to overcome these problems and increase the antigen specific immunological 
responses. The most important of these are discussed below.
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Microencapsulation technologies
Microspheres
Some of the problems associated with oral vaccination can be circumvented by 
encapsulation of the antigen into microscopic capsules. The gastrointestinal tract is a very 
harsh environment, incorporating the antigen within a capsule protects it from enzymatic 
degradation and may selectively enhance the uptake of the antigen into the inductive sites 
of the CMIS.
Biodegradable microspheres are around 5-200 pm in diameter and made from synthetic 
polymers. Their use has been investigated by several groups for vaccination at mucosal 
surfaces (Maloy et al., 1994; McQueen et al., 1993; Moldoveanu et al., 1993). The 
microspheres themselves can be manufactured easily (Aguado and Lambert, 1992; Morris 
et al., 1994) and once dried are very stable allowing transport and delivery to the most 
remote regions of the world. Orally presented microspheres are selectively taken up into 
Peyer's patches by M cells (Eldridge et al., 1990). The antigen is then slowly released 
ready for presentation to the immune system by diffusion through the matrix pores and by 
slow degradation of the microsphere itself (Morris et al., 1994). The size of the 
microparticle plays an important role in its adjuvanticity. Smaller particles in the 
nanometre range are more efficient at inducing immunological responses than those in the 
micrometer scale, this may be due to an improved uptake of the smaller "nanospheres" by 
M cells (O'Hagan, personal communication).
By varying the proportions of the constituent polymers (polylactide and polyglycolide) the 
release period can be varied from a few days to up to one year (Aguado and Lambert,
1992). This opens up the possibility of using more than one preparation of microspheres
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with different release rates in the same oral vaccine. This is the concept of controlled 
release vaccines where both priming and boosting doses of antigen can be given in the 
same application (Aguado, 1993).
Microspheres have been used successfully to elicit cytotoxic T cell and mucosal IgA 
responses against poorly immunogenic antigens such as ovalbumin (Maloy et al., 1994), 
and when administerd orally, they induced protective immune responses against viral 
(influenza, Modoveanu et al., 1993) as well as bacterial (E.Coli, McQueen et al., 1993) 
infections.
Liposomes
Liposomes have long been used as delivery systems for systemic vaccines, hormones, and 
genetic material. It was observed many years ago that phospholipids and other polar 
amphiphiles in an aqueous environment form closed spherical membranes comprising of a 
bimolecular sheet (lamellae) of lipids (Bangham et al., 1995). Depending on the method 
of production liposomes can take various forms with sizes ranging from 2 0  nm to 2 0 0  pm, 
comprising unilamellar or multilamellar sheets (see review by Gregoriadis, 1990).
The adjuvant action of liposomes in mucosal vaccination probably depends on the route of 
application, and whether the antigen is located within the lumen or associated with the 
membrane of the liposome (Shahum and Therien, 1994). Like microspheres, liposomes 
may protect an antigen through the harsh intestinal environment and be taken up by 
Peyefs patches (Childers et al., 1990). Multilamellar liposomes create an antigen depot 
and slowly release their load as each layer is degraded (Aguado and Lambert, 1992). 
Antigens which are poorly immunogenic when administed by the oral route, e.g. soluble
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ovalbumin (Vadolas et a l, 1995) and peptides (Friede et a l, 1994) can be rendered 
immunogenic by virtue of being bound to the membrane or entrapped within the lumen of 
the liposomes. Small liposomes (20nm-5pm) are efficiently taken up by antigen 
presenting phagocitic eells and may initiate T cell stimulation through the influence of IL- 
1 (Shahum and Therien, 1994).
A different method of adjuvant action has been described during immunisation of the total 
respiratory tract (RT, de Haan et a l, 1995a, 1995b). Instillation of liposomes into the RT 
was thought to abrogate the suppressive role of alveolar macrophages, such that simple 
application of inactivated influenza antigen was sufficient to induce an antigen specific 
immune response. This effect is independent of any positive effects on antigen 
presentation, as evidenced by the observation that instillation of liposomes up to 2  days 
prior to application of influenza antigen was sufficient to enhance the influenza specific 
immune response.
Liposomes represent a versatile carrier system which offers the possibility of 
supplementing the vaccine, and working additively, with other immunostimulators such as 
IL-2 (Abraham and Shah, 1992), monophosphoryl lipid A (Zhou and Huang, 1993), 
muramyldipeptide (Nerome et al., 1990), or cholera toxin B subunit (Zhou et al., 1995). 
Mucosal vaccinations with liposomal antigen preparations have been used successfully to 
protect animals fi’om bacterial {Pseudomonas aeruginosa Girod de Bentzmann et al.,
1994; Bordatellapertussis Guzman et al., 1993; Shigella flexneri, Mallet et al., 1995), and 
viral (measles: de Haan, 1995; influenza: LI Guink et al., 1989; Friede e/ al., 1994; de 
Haan et a l, 1995) infections.
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ISCOMs
Immune stimulating complexes (ISCOMs) are closely related to liposomes and are 
formed simply by the addition of the saponin Quil A to cholesterol, forming 40-90 nm 
cage-like structures (Morein et al., 1984). ISCOMs have been used for mucosal 
vaccinations against numerous antigens (McI Mowat and Donachie, 1991) and can induce 
both IgA and IgG at the mucosal surface. The potency of ISCOMs to adjuvant immune 
responses after oral presentation can be attributed to their efficient uptake by M cells and 
macrophages as a consequence of their sub-micrometer size, and also the adjuvant effect 
of Quil A. A key feature of these vaccines is that after oral administration of non­
replicating antigens, instead of the normal oral tolerance, the ISCOMs not only elicit 
increases in mucosal antibody but also induce systemic CTL responses (McI Mowat et al., 
1991; Lipford et al., 1995).
In general, systemic vaccination does not induce antibodies at the mucosal surface. This is 
not always the case however, sine systemic vaccination of horses with inactivated equine 
influenza virus in the form of ISCOMs resulted in the stimulation of influenza specific 
nasopharyngeal antibody (Hannant et a l, 1988). The kinetics of antibody appearance and 
duration implied that a proportion of the antibody (30-60%) was locally produced.
Recombinant Vectors
Live attenuated vaccines and recombinant vectors expressing foreign genes are efficient at 
stimulating immunological responses at the mucosal surface after a topical application. 
This is probably because of their ability to mimic a natural infection and invade tissues.
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producing large amounts of the expressed antigen, inducing endogenous processing and 
theoretically stimulating the immune system by through the MHC class 1 pathway.
Bacterial vectors
Carter and Collins (1974) showed that the initial site of Salmonella typhimurium infection 
was Âe Peyer's patch. As this is the major IgA induction site in the murine gut, this work 
sparked interest in using Salmonella mutants as mucosal vaccine delivery systems.
Several different types of genetically engineered live attenuated bacterial mutants have 
been developed which are effective as live vaccines, e.g. the PhoP mutant which is no 
longer able to survive in macrophages (Miller et al., 1990), and the AaroA mutant of S. 
typhimurium which retains its ability to colonise Peyer's patches but is avirulent because 
of its requirement for p-aminobenzoic acid (PABA) which is not found in the animal host 
(Hoiseth and Stocker, 1981).
Recombinant Salmonella mutants can be constructed to express foreign antigens and have 
been used as mucosal vaccines via several topical routes (Hopkins et al., 1995). Valentine 
et al. (1996) used an AaroA mutant transfected with the Simian Immunodeficiency Virus 
(SIV) p27 gag gene during a study of oral vaccination. The mutant was designed in such a 
way that expression of the SIV gene was up-regulated after being phagocytosed by a 
macrophage. In this way oral vaccination induced high levels of SIV specific mucosal 
sigA and systemic CTL responses.
The Salmonella mutant vaccine delivery systems probably exert their adjuvant action by 
stimulating Thl dominant responses. Van Cott et al. (1996) took T cells derived from PP 
after an oral vaccination with the attenuated recombinant S. typhimurium (BRD 847)
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expressing a fragment of tetanus toxin (TT). The isolated T cells secreted increased 
quantities of INF-y, IL-2, and IL-10 but not the classical mucosal cytokines IL-4 and IL-5. 
Increased levels of macrophage derived IL-6  was also reported. A single dose of this 
vaccine induced subclasses of immunoglobulins commonly associated with Thl 
responses, i.e.TT specific serum IgG2a.
Viral vectors
Live viral vectors which mimic natural infections have also been investigated. The most 
widely used vector is vaccinia virus although others have proved successful. For example, 
Gallichan and Rosenthal (1995) constructed a recombinant adenovirus expressing Herpes 
Simplex Virus (HSV) gB protein to vaccinate mice intranasally, resulting in high titres of 
serum and vaginal HSV specific IgA and IgG.
Recombinant vaccinia viruses are attenuated in such a way as to allow replication and 
expression of the inserted gene. Sutter et al. (1994) developed a strain of vaccinia virus 
(MVA) which expressed all of its gene products but was not able to assemble into 
infectious virus. Intranasal instillation of this construct into mice, containing the genes for 
nucleoprotein (NP) and haemagglutinin (HA) of influenza virus, elicited serum HI 
antibody, CTL, and fully protected the animals from influenza infection.
As with liposomes and microcapsules, recombinant DNA technology offers the 
opportunity to deliver immuno-stimulating cytokines to the cells involved in the induction 
of the immune response. For example Janardhana et al. (1994) demonstrated that 
incorporation of the IL-5 gene into vaccinia virus increased the recruitment of antibody 
secreting cells to the lung.
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Despite the promising results obtained with these types of vaccines, there remain major 
drawbacks in the use of live attenuated vectors. Any attenuated vector always carries a 
risk of reversion to its pathogenic wild-type. Furthermore, problems in isolating attenuated 
vectors from their wild-type parents creates problems of unpure attenuated vaccine strains. 
These dangers combined with those associated with the use of recombinant DNA in the 
generation of the genetically altered organisms, impart acknowledged safety risks on any 
future vaccine candidate. Such vaccines in todays world of ever tightening safety control 
face ever increasing problems in regulatory licensing of the product. Although, admittedly 
this problem may be less significant in the non-human field of vaccine development.
Another potential problem with live vectors is the fact that after an initial usage, the vector 
may elicit not only an immune responses directed against its foreign gene, but also against 
itself. This may preclude the use of a particular vector for repeated vaccinations as long as 
there remains immunity to it. For example Rooney et al. (1988) showed that a previous 
experience of a vaccinia influenza vaccine decreased the HSV-specific immune responses 
elicited after a subsequent vaccinia HSV vaccination.
Recently, two very interesting departures from established vaccination procedures have 
broadened the range of vaccination regimes and delivery vehicles. Work in the expression 
of bacterial DNA in tobacco and potato plants has developed the possibility of using 
transgenic food to produce huge quantities of oral vaccine. By feeding mice with potato 
which expressed the E. coli heat labile toxin B chain (LTB) endotoxin gene, Haq et al. 
(1995) were able to elicit LTB-specific gut and serum neutralising antibodies.
Palatability, in these cases may hinder their use in humans as cooking may abrogate 
antigenicity. Studies are underway, however, in other foodstuffs such as the banana which
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will circumvent these problems. This cheap method of producing large quantities of easily 
administered vaccine has a great potential use in developing countries.
Systemic vaccination with conventional vaccines does not usually stimulate significant 
antibody secretion onto the mucosal surface. Daynes (Daynes et a/.,1996) attempted to 
modulate the immune response after a systemic vaccination in order to stimulate mucosal 
antibody. T cells derived from lymph nodes associated with the mucosal surface express a 
different cytokine profile (Th2) compared with those of peripheral lymph node T cells 
(Thl). He found that after an intramuscular vaccination, the Thl cytokine profile of the 
local lymph node could be switched to a Th2 profile if the vaccine was supplemented with 
the hormone la,25-dihydroxy vitamin D3 . Using this procedure. Hepatitis B specific IgA 
antibody was induced in the urogenital, lachrymal, faecal, and oral secretions of mice after 
vaccination in the hind footpad (Daynes et al., 1996).
Nucleic Acid Vaccines
Intramuscular injection of naked DNA containing the nucleotide sequence encoding 
pathogen specific antigens results in uptake and expression of the protein by muscle cells 
(review Feigner and Rhodes, 1991) thereby eliciting humoral (Fynan et al., 1993) and 
cytotoxic T cell responses (Ulmer et al., 1993). Encapsulation of viral mRNA in 
liposomes also induces virus specific CTL after parenteral vaccination (Martinon et al.,
1993). These vaccination methods have been shown to confer protection from viral 
challenge (Webster et al., 1994).
This field of vaccine research is newly emerging and does not benefit from the advantage 
of hindsight as seen in the field of live vaccines. As such, data on vaccine safety has to be
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observed with the knowledge that only limited studies have been performed on a relatively 
small scale. It should be remembered there are potential safety hazards predicted with 
nucleic acid vaccines, such as inopportune vaccine incorporation into the host genone 
causing irreversible genetic damage. Such events could theoretically lead to cancer if the 
region responsible for a proto-oncogene is disrupted.
Mucosal delivery of DNA vaccines against viral antigens (Influenza HA) has also been 
shown to elicit mucosal and systemic antibodies that protect recipient mice from viral 
challenge (Fynan et al., 1993).
This is an exiting new research field which may offer valuable possibilities to stimulate 
strong humoral and cell mediated responses to defined antigenic sequences. Potentially 
safe and stable polyvalent vaccines are also a very attractive prospect for the poorest parts 
of the world where multiple vaccinations are too costly. Single application of polyvalent 
recombinant DNA by nasal vaccination could theoretically protect an individual from 
many different mucosal infection
Cholera Toxin
Cholera toxin (CT) and its non-toxic subunit CTB are both well established, potent, 
mucosal adjuvants which exhibit a wide variety of stimulatory and inhibitory actions (for 
a review see Snider, 1995). They have been used by a number of groups in mucosal 
vaccines which are characterised by large mucosal sIgA and serum IgGl responses and 
conferring protection from various viral (influenza, Tamura et al., 1988; Bovine 
herpesvirus 1, Israel et al., 1992) and bacterial pathogens {Pseudomonas aeruginosa, 
Abraham and Robinson, 1991; Helicobacter felis, Lee and Chen, 1994).
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CT is a heterohexameric bacterial endotoxin normally produced in the intestinal lumen by 
Vibrio cholerae and shares 80 % homology with the heat-labile enterotoxin produced by 
Escherichia coli (LT) It consists of a toxigenic A chain (CTA) supported by a pentameric 
ring of B subunits (CTB). In the normal course of events the B pentamer binds GMl 
ganglioside, present on the membrane of intestinal epithelial cells, and inserts the A chain 
into the cytosol of the target cell. Reduction of the A chain intracellularly releases an Al 
fragment capable of binding NAD and catalysing the ADP ribosylation of Gsa, a GTP- 
binding regulatory protein associated with adenylate cyclase. The result is a sharp increase 
in cyclic AMP production (cAMP, Spangler, 1992).
The precise role of the two subunits in the adjuvanticity of CT is currently being 
evaluated. Each subunit CTA and CTB probably has individual mechanisms which can 
work independently or in cooperation with each other. For example, CTA increases 
intracellular cAMP, but this alone is not enough to induce an immune response. CTB 
mixed with the cAMP inducer forskolin similarly fails to stimulate an immune response. 
This observation suggests that mere binding of CTB to GMl ganglioside or an increase in 
intracellular cAMP is not sufficient and a mixture of the two are required (Tamura et al.,
1995). It is clear nonetheless that some commercial sources of CTB can be used to 
optimal effect because of contamination with trace amounts (less than 0.1 %) of CTA ~ 
(Tamura e/a/., 1994).
When used in mucosal vaccines CT can either be simply mixed or covalently conjugated 
with the antigen to exert its adjuvant effects. As mentioned previously, simple application 
of antigen to the mucosal surface may result in suppression of systemic responsiveness to 
that antigen, a mechanism termed “oral tolerance”. CT and CTB have always been 
observed not to establish oral tolerance to themselves, and additionally have the effect
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when co-administered with an unrelated antigen of “breaking” the establishment of oral 
tolerance to that antigen (Elson et al., 1984). Recent findings have highlighted differences 
in the roles of the CT subunits and identified the need for care in this area. Intranasal 
vaccination with a CTB-antigen conjugate, in the absence of CTA, not only does not 
induce a mucosal immune response to the antigen but also enhances the antigen specific 
systemic tolerance (Sun et al., 1994; Wu and Russell, 1994). It is suspected that the 
tolerance breaking properties, previously attributed to both CT and CTB, are selective for 
CT. Thus the conflicting literature based on commercially available CTB might be 
explained by low levels of contaminating CT (Czerkinsky and Holmgren, 1995).
CT has been demonstrated to exert wide-ranging effects at almost all stages of the immune 
response including uptake of antigen, stimulation of antigen presentation, T-helper 
stimulation and proliferation of B cells. It can also be used in the face of pre-existing anti- 
CT immunity (Tamura et al., 1989; Wu and Russell, 1994). Once ingested, CT can be 
observed in the PP and intestinal LP within one hour (Lindner et al., 1994). One of its first 
effects on the immunological responses to bystander antigens is that CT increases the 
permeability of the mucosal epithelium to lumenal proteins (Lycke et al., 1991; 
Gizurarsonc/a/;, 1992).
Although CT has been shown to stimulate antigen presentation by boosting IL-1 
production of APC's in vitro (Lycke et al., 1989; Hirabayashi et al., 1992) the major facets 
of its adjuvanticity probably lie with the regulation of the cytokine environment within 
the mucosal induction site and the inhibition of oral suppression. Cytokines commonly 
associated with a Th2 type profile (Mosmann and Coffman, 1989) have been shown to be 
important in the generation of IgA production (Murray et al., 1987) and appropriately, PP 
have also been shown selectively to produce Th2 cytokines (Lagoo et àl., 1994; Hiroi et 
al., 1995). In contrast with other vectors such as S. typhimurium, which specifically
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enhance a Thl type cytokine profile in the mouse gut (Klimpel et al., 1995; Van Cott et 
al., 1996), the cytokines stimulated by CT are of the Th2 type (IL-4 and IL-5: Xu-Amanb 
et al., 1994; IL-6  and IL-10: Klimpel et al., 1995).
Once CT has reached the mucosal induction site it exerts regulatory effects on both T and 
B cells and succeeds in establishing immunological memory in both of these cell types 
(Vajdy and Lycke, 1992 and 1993; Jertbom et al., 1994). Normal feeding of antigen 
inhibits priming of CD4+ve T cells and systemic antibody responses while activating CDS 
+ve t  cells which may exhibit a suppresive fimction (Ke and Kapp, 1996). In contrast 
when CT is fed to mice it greatly promotes selective priming of CD4+ve T cells through 
the action of interleukins (IL)-2,4, 5 ,6 ,10, and INF-y (Homquist and Lycke, 1993) and 
abrogates the induction of CD8+ve suppressor cells (Elson et al., 1995). The responses of 
mucosal B-cells are also significantly enhanced. CT has been shown both in vitro and in 
vivo to induce isotype switching of IgM+ve B cells to produce IgA and IgG (Lehman et 
al., 1988; Lycke and Strober, 1989; Chen and Strober, 1990). This effect is probably 
mediated by the actions of IL-4, IL-5, and IFNy (Chen and Strober, 1989).
1.2.4. Summary
Mucosal application of antigen together with adjuvant has proved to be a powerful tool in 
the protection of animals from à wide variety of respiratory and gastrointestinal 
pathogens. Mucosal vaccinations have various advantages over their systemic 
counterparts. They may prevent the initial infection of the epithelium (Israel et al., 1992; 
Takada and Kida, 1996), they may be responsible for greater cross protection fix)m newly 
emergent virus strains (Liew ei al., 1984; Tamura et al., 1990; Asanuma et al., 1995), and
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can be easily and rapidly administered by people that require no special training and are 
therefore ideally suited for use in developing countries (Aguado and Lambert, 1992).
Systemic vaccination, in some cases, may induce protective immunological responses in 
terms of protection from lethal challenge dose of pathogen. In a recent paper, Takada and 
Kida (1996) showed the importance of immunological mechanisms present at the mucosal 
surface. They observed that chickens immunised systemically were protected from 
challenge, yet still supported virus growth in the respiratory sinus. In contrast, intranasal 
vaccination of chickens induced mucosal immunological responses which prevented virus 
replication in sinuses.
The immunological mechanisms associated with the protection stimulated by a mucosal 
vaccination are located at the site of.initial infection, and serve to prevent pathogen-cell 
contact or replication of infectious particles. This feature of mucosal immunity may be 
very important in the defence against pathogens that quickly cross the epithelial barrier 
and establish infections and latency elsewhere within the host. One example where this is 
the case is equine herpesvirus-1 (EHV-1). EHV-1 is observed to cause respiratory disease, 
cell associated viraemia in peripheral blood mononuclear cells, and establishes latency 
(Allen and Bryans, 1986). The virus crosses the epithelial barrier very rapidly such that 
antigen is detected in respiratory tract associated lymph nodes as soon as 12 hours after 
infection (Kydd et al., 1994). The rapid intracellular localisation of EHV-1 indicates the 
important role of cellular immunity in early recognition of virus-infected cells and 
recovery from infection (Kydd et al., 1994). However, work performed in cattle has 
shown that mucosal vaccination protects cattle from bovine herpesvirus-1 (BHV-1) 
infection, suggesting that a strong mucosal barrier present at the mucosal suiface could 
prevent the penetration of virus and establishment of latency (Israel et a l, 1992).
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1.3 Influenza
1.3.1 The influenza virus
Influenza virus is a member of the orthomyxoviridae family. The virion is a pleomorphic 
negative-stranded RNA virus of about 80-120 nm in diameter. The virus particle consists 
of a host cell derived lipid bilayer envelope encasing the viral genome associated core. 
The genomes of influenza viruses are comprised of eight single-stranded RNA chains 
together encoding at least ten different proteins (Skehel and Schild, 1971).
The outer lipid bilayer contains two glycoproteins, haemagglutinin (HA) and neuramidase 
(NA), which are embedded in the membrane via their hydrophobic ends (figure 1.4). 
Directly beneath this lipid envelope is a protein capsule made up of matrix (M) protein, 
which holds the RNA fragments connected to the nucleocapsid (NP) and polymerase 
proteins (PI, P2, and PA). The viral genome also encodes two non-structural proteins that 
are not incorporated into the virion (NSl and M2).
Influenza viruses are classified on the basis of their type-specific internal M and NP 
proteins. Thus influenza B and C viruses are restricted to human infections, while 
influenza A viruses have been isolated from disease outbreaks in many animal species. 
Type A viruses are further subtyped depending on their specific glycoprotein content. 
Fourteen distinct HA and nine NA molecules have been identified in avian viruses, whilst 
only two types, H7N7 (A/equine/1) and H3N8 (A/equine/2) have been recognised in 
equine influenza outbreaks.
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Haemagglutinin
Of the total viral protein HA makes up about 25%, it is the major membrane bound 
protein. It is found as 10-14 nm spikes distributed evenly over the surface of the virion. It 
is responsible for the attachment of the virus onto the target cell receptor, sialic acid, and 
also mediates fusion of the endocytosed virus with the endosomal membrane. As such HA 
is the major target for neutralising antibodies. The HA molecule is a trimer of identical 
non-covalently linked subunits (Wilson et al., 1981). It is triangular in cross section for 
much of its length, but spreads out at its end to reveal the three constituent parts. Each 
subunit is synthesised as a single polypeptide chain but postranslational events cleave the 
N-terminal region leaving two proteins, HAl (51 kDa) and HA2 (24kDa). Nucleotide 
sequences for the HA of both equine subtypes H3 and H7 have been determined (Daniels 
et al., 1985; Gibson et al., 1992; Binns et a l, 1993). While major antigenic differences 
have been identified between the subtypes, minor antigenic "drift" changes may occur 
within a subtype to allow the emergence of a new strains of influenza viruses (Daly et al.,
1996).
Neuramidase
Neuramidase (NA) is the second membrane bound glycoprotein on the viral surface, 
making up around 10 % of total viral protein. Its role is to cleave any terminal sialic acid 
residue from glycoconjugates (Gottschalk, 1957) and is therefore responsible for cleaving 
the HA of a newly formed virus from the sialic acid containing receptor on the host cell, 
thereby releasing the virus and preventing reabsorbtion into the cell (Griffin et al., 1983).
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Figure 1.4 Equine influenza virus.
A three dimensional diagram showing the structure of an influenza virion. M, M-protein; 
NA, neuramidase; RNP, ribo-nucleoprotein; HA, haemagglutinin.
M NA RNP HA
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NA has also been implicated in the fusion of viral and cell membranes (White et a/., 1982). 
Also, NA may help the transmission of virus particles across the mucin secretion barrier 
present on respiratory epithelia by cleaving non-specific HA inhibitors (Klenk and Rott, 
1988).
The mushroom shaped spikes of the NA molecule are made up of four identical subunits, 
each having a molecular weight of around 60 kDa. The NA molecule has a box-shaped 
head attached onto a thin stalk, the length of which appears to be related to host range and 
virus virulence (Castrucci and Kawaoka, 1993). Antigenically the NA is strain specific 
and displays antigenic variation within a subtype and major antigenic differences between 
the subtypes. Only two subtypes, N7 (A/equine/1) and N8 (A/equine/2), have been 
identified in equine influenza viruses.
Nucleoprotein
Nucleoprotein (NP) is a major group-specific internal protein that distinguishes between 
influenza A, B, and C viral types, whilst showing little variation between subtypes. It is a 
protein of around 60 kDa which associates, together with the polymerase molecules, and 
the viral RNA to form ribonucleoprotein (RNP) particles. As well as this structural role, 
NP is also involved in the replication of the viral genome (Skorko et al., 1991). Diagnosis 
of equine influenza infection is routinely performed by detection of NP antigen by capture 
ELISA techniques from nasal swab samples (Cook et al., 1988).
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Matrix proteins
The matrix protein (M) is also a group-specific antigen, and is the most abundant internal 
protein associated with the infiuenza virus. This protein, of approximately 27 kDa, lines 
the inner surface of the lipid bilayer and accounts for up to 47% of the total virus protein. 
A second M protein (M2) is found in large quantities in the infected cell and small 
amounts in the intact virion. The M2 protein is a highly conserved transmembrane ion 
channel which serves to regulate the pH of the infected cell and resultant virion (Sugrue 
and Hay, 1991). Monoclonal antibodies against the M2 protein reduce viral growth in 
tissue culture (Zebedee and Lamb, 1988), and vaccination of mice with recombinant M2 
protects them from heterologous infiuenza challenge (Slepushkin et al., 1995).
The polymerase and non-structural proteins
Together with NP and viral RNA, three polymerase molecules PI, P2, and PA aggregate 
to form the RNP particles, and are the largest infiuenza virus proteins at 96, 87, and 85 
kDa respectively. They are associated with the expression of the viral genome within the 
nucleus of the infected cell.
Two so-called non-structural proteins are found in large quantities in the infected cell NSl 
and NS2 (23 and 11 kDa respectively). NSl is only found in infected cells and is involved 
in the regulation of viral gene expression by controlling the export of mRNA from the cell 
nucleus. Qui and Krug (1994) postulated that accumulation of NSl in the nucleus in the 
early stages of infection binding of the NSl to the poly A tails would block the exit of all 
mRNA from the nucleus. The cellular mRNA would then be cleaved by the viral 
polymerases, leaving the capped primers free to be used for further viral mRNA synthesis.
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The cleaved cellular RNA would be unable to leave the nucleus and would be degraded, in 
this manner the NSl protein hijacks the cells protein synthesis apparatus for purely viral 
proteins.
NS2 protein is a protein formed from a spliced product of NSl mRNA. It localises in large 
quantities in the nucleus of the infected cell and is thought to be involved in viral protein 
synthesis. It has also been detected in small amounts in purified viruses (Richardson and 
Akkina, 1990).
1.3.2 Equine influenza
Equine infiuenza was first recognised during a natural outbreak in 1956 (Sovinova et al., 
1956). This virus, designated A/equine/1/Prague/56 was identified as a H7N7 infiuenza 
virus. No H7N7 outbreak has been reported since 1979. In 1963, an infiuenza virus 
(A/equine/2/Miami/63, H3N8) was isolated which showed major antigenic differences 
from the Prague '56 virus (Scholtens and Steele, 1964) and since then, there have been 
sporadic epizootics of H3N8 equine infiuenza, with each responsible virus differing only 
slightly from the previous isolate due to antigenic drift (Daly et al., 1996).
The virus is inhaled in microscopic aerosol and infects the ciliated epithelial cells of the 
upper respiratory tract (URT). Multiplication and viral release destroys these cells and the 
infection spreads throughout the URT including the nasal turbinates, nasopharynx, larynx, 
and trachea (Wilson, 1995). The function of the mucocilliary escalator becomes 
compromised due to deciliation of the epithelium from days 3-4 post infection (Sutton, 
personal communication. In Press 1997). The loss of mucus clearance allows invasion of 
opportunistic nasal bacteria, most commonly Streptococcus zooepidemicus or Pasturella /
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Actinohacillus spp.. Inflammation of the lung leads to epithelial erosion and oedema of 
the mucosae. Bronchoalveolar lavage sampling over the course of an infection reveals a 
neutrophilia and depletion of macrophages between days 3-7 after infection, with no 
significant changes to lymphocyte numbers (Sutton et al, 1996). Clinical signs might 
include, pyrexia (105 °C, days 3-7), dry non-productive cough, serous nasal discharge 
which may become purulent, lethargy, anorexia, increased breathing and heart rate, 
hyperaemia of the nasal and conjunctival mucosae, lacrimation, limb oedema, muscle 
soreness and spasms (Wilson, 1995).
1.3.3 Immunological responses to equine influenza infection
Experimentally induced influenza infection with reproducible clinical signs has been used 
to investigate the immunological responses to infection and to study the correlates of 
immunity (Mumford et a l, 1990). Primary infection with influenza results in stimulation 
of antigen specific IgG, IgA, and IgM antibodies in serum and nasopharyngeal and 
tracheal washes; although this antibody is rather short lived (Hannant et a l, 1988a and 
1989a). Genetically restricted cytotoxic lymphocytes (CTL) have also been detected in the 
peripheral blood mononuclear cells (PBMC) 14 days after infection (Hannant et a l, 1988a 
and 1989b).
1.3.4 Immunological correlates of immunity to influenza Infection
It has proved difficult to define the relative contribution of serum and mucosal antibodies 
and cellular immune responses to the protection of horses from influenza challenge. The 
functional significance of local antibody has been difficult to elucidate in the presence of
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high levels of background serum antibody (Rouse and Ditchfield, 1970). In other species 
such as humans, influenza vaccine trials have indicated an important role for local 
antibody in protection from infection, and shown that protection is most strongly 
correlated with nasal HA specific IgA (Clements et al., 1984 and 1986; Tomoda et al.,
1995). Passive administration of virus specific IgA into the nares of recipient mice before 
challenge protects them from experimental influenza infection (Tamura et al., 1990).
Also, influenza specific secretory (s)IgA injected into mice can be observed to locate to 
the mucosal surface and protect the URT from infection (Renegar and Small, 1991). sIgA 
may also be a major mediator of cross-reactive protection from heterologous influenza 
infection (Liew et al., 1984; Tamura et al., 1990; Asanuma et al., 1995). There have been 
many roles proposed for sIgA in protection of the mucosal epithelium against influenza 
infection (Outlaw and Dimmock, 1990 and 1991). These include the creation of a mucosal 
barrier across which virions cannot pass and prevention of binding to the target cell 
(Taylor and Dimmock, 1985), intracellular neutralisation of viral growth during IgA 
transport (Mazanec et al., 1995), and excretion of IgA-antigen complexes formed in the 
lamina propria after an infection (Kaetzel et al., 1991).
After an influenza infection, equids exhibit clinical immunity to rechallenge with 
homotypic virus for up to 1 year in the absence of residual circulating antibody, 
suggesting a role for other mechanisms of immunity (Hannant et al., 1988b). This feature 
contrasts with the situation after vaccination with inactivated antigens, where there is a 
strong correlation between protection from homologous virus infection and the amount of 
circulating antibody directed against the virus HA (Mumford et al. 1983, 1988). However, 
once this serum antibody has declined, the animals become susceptible to infection.
Equine influenza-specific CTL has been observed after infection (Hannant et al., 1988a 
and 1989b), but their role in protection from rechallenge has not been studied in detail.
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Influenza-specific CTL in other species have been extensively reviewed (Askonas et al., 
1982; McMichael, 1994). Briefly, CTL responses have been detected against the majority 
of structural and non-structural influenza proteins including, HA (Zweerink et al., 1977), 
NP (Yewdell et al., 1985), Ml (Gotch et al., 1987) and the polymerase molecules and 
NSl (Bennink et al., 1987). CTL responses against conserved proteins such as NP and M 
protein are thought to be the main mediators of cross-reactive cytotoxicity. HA-speciflc 
CTL probably only contribute to the immunological effector response against homologous 
virus (Zweerink et al., 1977). While there are reports of CTL alone confering protection 
from influenza infection (McMichael et al., 1983a), they are commonly thought to be 
responsible for virus clearance during the recovery phase of infection, and thereby 
limiting clinical disease (McMichael, 1994).
As neutralising antibody is directed primarily against HA, antigenic and genetic variation 
of influenza viruses over time renders the protection engendered by humoral responses, 
induced by infection or vaccination, progressively less efficient (McMichael, 1994). 
However, cross-reactive CTL still recognise these emergent viruses due to their restriction 
for conserved proteins such as M and NP. In humans the immunological memory of these 
CTL can be as long as 4 years (McMichael et al., 1983b). This persistent quasi-immunity 
of inefficient humoral activity and long cytotoxic T cell memory gives rise to problems in 
heavily vaccinated populations such as the equidae. Vaccination with vaccines containing 
antigenically distant viral strains induces humoral immune responses >\diich may be 
inefficient in neutralising newly emergent viral strains, thereby potentially allowing 
infections of vaccinated horses which are sub-clinical and permit nasal virus shedding to 
further propagate the virus outbreak (Mumford, 1992).
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1.4 Perspectives for mucosal vaccination
The important role of mucosal immunity in protection from human influenza (Clements et 
al., 1984 and 1986; Tomoda et al., 1995) has spurred interest in mucosal vaccination with 
inactivated influenza antigen and the potent mucosal adjuvant CT (Tamura et al., 1988, 
1990,1994,1995; Hirabayashi et al., 1992). From close examination of the literature, it 
has become clear that mucosal vaccinations comprising CTB and inactivated influenza 
antigens could hold several advantages over conventional vaccines in horses.
1) With conventional vaccines, which rarely induce any antibody at the mucosal 
surface, an infection can only be arrested once the virus has infected and established itself 
within an epithelial cell. Systemic vaccination with an antigenically distant virus strain 
may allow a sub-clinical heterologous infection to develop, during which virus may be 
shed from the nares of infected individuals. In this manner, an influenza outbreak may be 
propagated within populations of heavily-vaccinated animals (Mumford, 1992). A 
nasopharyngeal influenza vaccine could induce large quantities of type specific and cross­
reactive IgA at the mucosal surface. This would prevent viral growth (Outlaw and 
Dimmock, 1990 and 1991; Taylor and Dimmock, 1985; Mazanec et al., 1995; Kaetzel et 
al., 1991), and also "mop up" free virus, thereby preventing nasal shedding.
2) It has been shown by many groups that protection from influenza infection with a 
heterologous virus is due, to a large extent, to sIgA present at the mucosal surface (Liew et 
al., 1984; Tamura et a l, 1990; Renegar and Small, 1991; Asanuma et al., 1995). 
Generation of influenza-specific sIgA is therefore a desirable goal of any successful 
influenza vaccine. This can best be achieved by vaccination via the mucosal surface 
(Mestecky, 1987). This function of sIgA to prevent infection with heterologous virus may
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be accounted for by the hypothesis that some of the mechanisms by which sIgA may 
prevent virus infection depend on its physical attachment to the virion and may be 
independent of the role of the target antigenic domain/epitope. The mechanism for this is 
purely speculative, potential mechanisms include locking virus in association with the 
mucus layer thus preventing attachment to epithelial cells (Israel et al., 1992), binding to 
viral particles whilst still inside the epithelial cell and transporting the antibody/antigen 
complex across the epithelium and releasing it into the airway lumen (Mazanec et 
al.,1995); and the neutralisation of free viral particles in the lamina propria and subsequent 
excretion through the sectretory component translocation mechanism (Kaetzel et 
a/.,1991). These mechanisms may depend on mere binding of IgA to the pathogen and not 
blocking any one particular function of the pathogen.
Thus establishment of IgA responses capable of binding newly emergent viral strains, as 
described above, may have a role in preventing the sub-clinical infections which otherwise 
may be permitted in the presence of immunoglobulins which neutralise virus via the 
blocking of a specific target epitope.
3) During an equine influenza infection, the recall of anamnestic immunological 
responses at the level of the mucosal surface is extremely rapid. The appearance of 
influenza specific immunoglobulins in the nasopharynx of these horses occurs within 4 
days of the infection (Hannant et al., 1989a). It is thought therefore, that a primed equine 
mucosal immune system has the potential to mount a protective immunological response 
very quickly after antigenic presentation. This feature of the mucosal immune system 
would allow a mass vaccination programme of stable yards, to induce swift protective and 
cross-reactive immunoglobulin responses, in the face of an epizootic.
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1.5 Objectives of the study
The aims of this study are three fold:
(i) To investigate the existence of the common mucosal immune system in the horse 
by observation of immunological responses after intranasal vaccination.
(ii) To induce influenza specific antibody responses at the mucosal surface and 
demonstrate anti-viral activity of those antibodies.
(iii) To investigate the efficacy of intranasally administered inactivated influenza 
antigen together with cholera toxin B chain, as a vaccination regime to protect 
horses from influenza infection.
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Chapter 2
Development and validation of methods to 
measure antibody levels and function in nasal
washes
Chapter 2. Development and validation of methods to measure antibody levels and 
function in nasal washes.
2.1 Introduction
The investigation of the mucosal immune system in a large animal like the horse, and its 
immunological responses after infection and vaccination, is furnished with problems of 
reproducible sampling. Generally, mucosal secretions have been collected by extraction 
fi-om absorbent swabs which were left in the nasal passage of the horse for long periods of 
time (Rouse and Angulo, 1970). This technique causes discomfort to the animal, and 
could cause erosion of the epithelium leading to "leakage" of systemically derived 
material into the nasal swab.
We have used a nasopharyngeal lavage technique to obtain antibody specifically firom the 
nasopharynx and nasal passages. However, samples collected in this way may inherently 
exhibit great variation in the concentration of components in the resultant nasal wash 
because of sampling manipulation error, uncooperative experimental animal, or other 
effects on the rate of production of nasal secretions (e.g. intercurrent respiratory disease). 
To overcome these effects, and allow interpretation of the resultant ELISA data, methods 
of standardising each nasal wash have been developed.
Many studies have been published on intranasal vaccination against influenza in other 
species which showed vaccination-induced antigen-specific mucosal immune responses. 
However, only rarely have these responses been demonstrated to possess anti-viral activity 
(Tamura et al., 1990). A major aim of this project was therefore to develop an assay to 
measure influenza virus specific neutralising antibody in nasopharyngeal washes.
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2.2 Materials and methods
2.2.1 Collection o f nasal wash samples
Ponies that were to have their nasopharynx lavaged were sedated using 0.2 ml of 
intravenous Domosedan [Veterinary Drug company]. After sedation was achieved a short 
length (roughly 6  inches) of clear PVC tubing (Portex, 6.5mm external diameter x 2.5 mm 
internal diameter) was inserted into one nostril of the horse and 50 ml of sterile PBS was 
instilled with a 50 ml syringe. The nasal wash lavage fluid was caught in a large sterile 
beaker as it dripped from the nostrils.
The method of nasal washing evolved over the course of these studies. An improved 
apparatus was developed for both nasal lavage and vaccine intillation (as described in 
chapter 4). The preferred apparatus is contructed with a spray nozzle at one end and is 
inserted to a point deemed to be at the entrance to the opening of the nasopharynx (see 
4.2.1). A good placement of the tubing was shown by a continuous stream of lavage fluid 
exiting the nasopharynx from both nostrils. Once back in the laboratory, the nasal washes 
were vortexed and clarified by centrifugation (1500xg, 5 mins). The supernatants were 
then collected and frozen at -20°C.
2.2.2 Collection o f Bronchoalveolar lavage (BAL) samples
The bronchoalveolar spaces of ponies were sampled using a variation of a blind lavage 
method first described by Dyer et al., (1983) and used in this department (Kydd et al.,
1996).
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2.2.3 ELISA to determine the influenza /  cholera toxin specific antibody in nasal washes 
/serum
A 96 well ELISA plate (Immulon 3, [Dynatech, cat. no. 011-010-3755\) was coated 
overnight, at 4°C with antigen diluted to 20 pg/ml in 0.05M carbonate/bicarbonate buffer 
pH 9.6 [Sigma, cat. no.C-3041]. Antigen was either cholera toxin B chain or influenza 
antigen (as described in 5.1.2.1). The plate was incubated for 1 hour at 37°C, in blocking 
buffer (phosphate buffered saline [Unipath Ltd, cat.no. BR14\), containing 0.05% Tween 
20 [Sigma, cat.no. P-1379], and 2% dried skimmed milk [Biorad, cat.no. 170-6404]) to 
block all free sites. The plates were washed thrice with washing buffer (phosphate 
buffered saline [Unipath Ltd, cat.no. BRI4], containing 0.05% Tween 20.
Nasal wash samples were added in duplicate and titrated from undiluted sample by double 
dilution to 1/128 across the plate. Sera were added at 1/50 dilution initilally and similarly 
titrated. The plates were incubated for 1 hour at 37®C and then washed thrice in washing 
buffer. To determine the antigen specific IgA, a monoclonal antibody (K129-3E7, kindly 
supplied by C.R. Stokes) which had been biotinylated using a commercial biotinylation 
kit [Amersham, cat. no. RPN 2202] was added diluted 1/300 in blocking buffer. To 
determine the antigen specific IgG, an affinity purified biotinylated goat anti-equine IgG ( 
y) [Dynatech, K&P, cat.no. 16-21-02] was used, diluted 1/1000 in blocking buffer. The 
plates were incubated for 1 hour at 37®C and then washed thrice in washing buffer. 
Streptavidin-horseradish peroxidase, (1:1000 [Amersham, cat.no. RPN 1231~^  diluted in 
blocking buffer, was added to all wells and incubated for 1 hour at 37®C. The plates were 
washed thrice with washing buffer and the chromagen 0-phenyldiamine (OPD [Sigma, 
cat.no. P6912]) diluted to 0.5 mg/ml in phosphate-citrate buffer, with sodium perborate 
[Sigma, cat.no. P-4922], was added. After 20 minutes for the eolour to develop the
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reaction was stopped, with 4M H2 SO4 , and the absorbence read at 490 nm (Dynatech 
ELISA plate reader, DIAS system).
2.2.4 ELISA to determine total IgA in a nasal wash sample
A 96 well ELISA plate (Immulon 4, [Dynatech, cat. no. 011-010-3855]) was coated 
overnight, at 4°C, with a monoclonal anti-equine IgA antibody (K129-2G5, kindly 
supplied by C.R. Stokes) diluted in 0.05M carbonate/bicarbonate buffer (pH 9.6 [Sigma, 
cat. no.C-3041]). The plate was incubated for 1 hour, at 37®C, in blocking buffer 
((phosphate buffered saline [Unipath Ltd, cat.no. BRI4], containing 0.05% Tween 20 
[Sigma, cat.no. P-1379], and 2% dried skimmed milk [Biorad, cat.no. 170-6404]) to block 
all free sites. The plates were washed thrice with washing buffer (phosphate buffered. 
saline [Unipath Ltd, cat.no. BR14], containing 0.05% Tween 20 [Sigma, cat.no. P-1379]).
Nasal wash samples were added and titrated across the plate from neat to 1/64. The plates 
were incubated for 1 hour at 37®C and then washed thrice in washing buffer. A second 
monoclonal antibody (K129-3E7, kindly supplied by C.R. Stokes) which had been 
biotinylated using a biotinylation kit [Amersham, cat. no. RPN 2202] was added diluted 
1/300 in blocking buffer. The plates were incubated for 1 hour at 37°C and then washed 
thrice in washing buffer. Streptavidin-horseradish peroxidase, (1:1000 [Amersham, cat.no. 
RPN 1231'\) diluted in blocking buffer, was added and incubated for 1 hour at 37®C. The 
plates were washed thrice with washing buffer and the chromagen 0-phenyldiamine (OPD 
[Sigma, cat.no. P6912]) diluted to 0.5 mg/ml in phosphate-citrate buffer, with sodium 
perborate [Sigma, cat.no. P-4922], was added. After 20 minutes for the colour to develop 
the reaction was stopped, with 4M H2 SO4 , and the absorbence read at 490 nm (Dynatech 
ELISA plate reader, DIAS system).
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2.2.5 ELISA to determine total IgG in a nasal wash sample
A 96 well ELISA plate (Immulon 3, [Dynatech, cat. no. 0II-0I0-3755\) was coated 
overnight, at 4®C, with a polyclonal rabbit anti-equine IgG (whole molecule) antibody 
[Sigma, cat. no. H90I5] diluted in 0.05M carbonate/bicarbonate buffer (pH 9.6 [Sigma, 
cat. no.C-3041]). The plate was incubated for 1 hour, at 37°C, in blocking buffer 
(phosphate buffered saline [Unipath Ltd, cat.no. BR14], containing 0.05% Tween 20 
[Sigma, cat.no. P-1379], and 2% dried skimmed milk [Biorad, cat.no. 170-6404]) to block 
all free sites. The plates were washed thrice with washing buffer (phosphate buffered 
saline [Unipath Ltd, cat.no. BRI4], containing 0.05% Tween 20 [Sigma, cat.no. P-1379\).
Nasal wash samples were added and titrated across the plate from undiluted to 1/64. The 
plates were incubated for 1 hour at 37°C and then washed thrice in washing buffer. An 
affinity purified biotinylated goat anti-equine IgG (y) [Dynatech, K&P, cat.no. 16-21-02] 
was then added to all wells, diluted 1/1000 in blocking buffer. The plates were incubated 
for 1 hour at 37°C and then washed thrice in washing buffer. Streptavidin-horseradish 
peroxidase, (1:1000 [Amersham, cat.no. RPN 1231]) diluted in blocking buffer, was added 
and incubated for 1 hour at 37°C. The plates were washed thrice with washing buffer and 
the chromagen 0-phenyldiamine (OPD [Sigma, cat.no. P6912]) diluted to 0.5 mg/ml in 
phosphate-citrate buffer, with sodium perborate [Sigma, cat.no. P-4922], was added. After 
20 minutes for the colour to develop the reaction was stopped, with 4M H2 SO4 , and the 
absorbence read at 490 nm (Dynatech ELISA plate reader, DIAS system).
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2.2.6 ELISA to determine total immunoglobulin in a nasal wash sample
A 96 well ELISA plate (Immulon 3, [Dynatech, cat. no. 0II-0I0-S755\) was coated 
overnight, at 4®C, with a polyclonal rabbit anti-equine IgG (whole molecule) antibody 
[Sigma, cat. no. H90I5\ diluted in 0.05M carbonate/bicarbonate buffer (pH 9.6 [Sigma, 
cat. no.C-3041]). This antibody was known to cross react with equine IgA. The plate was 
incubated for 1 hour, at 37°C, in blocking buffer (phosphate buffered saline [Unipath Ltd, 
cat.no. BRI4], containing 0.05% Tween 20 [Sigma, cat.no. P-1379], and 2% dried 
skimmed milk [Biorad, cat.no. 170-6404]) to block all free sites. The plates were washed 
thrice with washing buffer (phosphate buffered saline [Unipath Ltd, cat.no. BRI4], 
containing 0.05% Tween 20 [Sigma, cat.no. P-757P]).
Nasal wash samples were added and titrated across the plate from undiluted to l/64..The 
plates were incubated for 1 hour at 37®C and then washed thrice in washing buffer. A 
polyclonal rabbit anti-equine IgG (whole molecule) horseradish peroxidase conjugate 
[Sigma, cat. no. A-9292] was then added to all wells and incubated for 1 hour at 37®C, 
diluted 1/1000 in blocking buffer. The plates were washed thrice with washing buffer and 
the chromagen 0-phenyldiamine (OPD [Sigma, cat. no. P69I2]) diluted to 0.5 mg/ml in 
phosphate-citrate buffer, with sodium perborate [Sigma, cat. no. P-4922], was added.
After 20 minutes for the colour to develop the reaction was stopped, with 4M H2 SO4 , and 
the absorbence read at 490 nm (Dynatech ELISA plate reader, DIAS system).
2.2.7 Competition ELISA to determine equine serum albumin (ESA) levels in nasal 
washes
A 96 well ELISA plate (Immulon 3, [Dynatech, cat. no. 011•010-3755]) was coated 
ovem i^t, at 4°C, with equine serum albumin (ESA, [Sigma, cat. no. A3434]) diluted to
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20 pg/ml in 0.05M carbonate/bicarbonate buffer (pH 9.6 [Sigma, cat. no.C-3041\). The 
plate was incubated for 1 hour, at 37®C, in blocking buffer ((phosphate buffered saline 
[Unipath Ltd, cat.no. BRI4], containing 0.05% Tween 20 [Sigma, cat.no. P-1379], and 
2% dried skimmed milk [Biorad, cat.no. 170-6404]) to block all free sites. The plates 
were washed thrice with washing buffer (phosphate buffered saline [Unipath Ltd, cat.no. 
BR14], containing 0.05% Tween 20 [Sigma, cat.no. P-1379^.
In a separate 96 well plate, nasal wash samples were added in triplicate and a titration of 
ESA was set up in 65pi volumes to act as a standard curve. 65 pi of a 1/500 dilution of a 
polyclonal rabbit antiserum, prepared within the department and shown to be specific for 
ESA (Hannant et al., 1989a), was added to all wells. After an incubation of 1 hour at 37° 
C, lOOpl volumes were transferred from this plate to the corresponding well of the ESA 
coated plate. The plate was incubated for 1 hour at 37°C and washed thrice with washing 
buffer. A polyclonal goat anti-rabbit IgG (whole molecule) horseradish peroxidase 
conjugate [Sigma, cat. no. A827S] was diluted 1/1000 in blocking buffer and added to all 
wells. After an incubation period of 1 hour at 37°C, the plates were washed thrice with 
washing buffer and the chromagen 0-phenyldiamine (OPD [Sigma, cat.no. P6912]) 
diluted to 0.5 mg/ml in phosphate-citrate buffer, with sodium perborate [Sigma, cat.no. P- 
4922], was added. After 20 minutes for the colour to develop the reaction was stopped, 
with 4M H2 SO4 , and the absorbence read at 490 nm (Dynatech ELISA plate reader, DIAS 
system).
An analysis of the results from the standard curve was performed using a 4-parameter 
logistic model. The mean ELISA data of the nasal wash samples (n=3) were calculated 
and using this figure the concentration of ESA present in the nasal wash was determined 
from the standard curve.
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2.2.8 Preparation o f influenza antigen used in the HI assay
Allantoic fluid containing A/Equi/2/Sussex/89 was grown as described in 5.1.2.1. To 40 
ml of infectious allantoic fluid, 500|il of a 10% v/v suspension of Tween 80 [BDH 
AnalaR] in PBS was added. After 5 minutes, 20ml of diethyl ether [BDHAnalaR] was 
added and the mixture stirred for 15 minutes at 4°C. The layers were allowed to separate 
and the virus containing aqueous layer removed and stored to allow any excess ether to 
evaporate overnight. The antigen prepared in this way was aliquoted into soda glass vials 
and stored at -70°C.
Prior to use in the HI assay, the amount of haemagglutination (HA) units in the virus 
preparation was determined. In a 96 well V-bottomed plate, 25 pi of antigen was titrated 
across the plate in doubling dilutions. The final volume was made up to 50pl by the 
addition of 25pl of PBS. 50pl of a 1% suspension of chicken red blood cells (RBC) was 
added and after an incubation of 30 minutes at room temperature the plate was tilted and 
the HA concentration was read. The last dilution where agglutination was complete was 
assigned 1 HA unit (HAU).
2.2.9 Haemagglutination inhibition (HI) assay
Non-specific inhibitors of HA in serum were inactivated with heat treatment in the 
presence of potassium periodate. Serum samples (150pl) were incubated with 300pl of 
freshly prepared potassium periodate (0.016M [BDHAnalaRif) for 15 minutes at room 
temperature. 150pl of 3% v/v glycerol [BDHAnalaR] in PBS was added and incubated for 
a further 15 minutes. The serum samples were then incubated at 56°C for 30 minutes.
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Nasal wash samples were dialysed against 2000 volumes of PBS for 2 hours at 4°C, and 
passed through a 0 .2 2 pm filter.
The inactivated sera, and sterile nasal wash samples, were titrated by doubling dilutions in 
PBS in V-bottomed microtitre plates in a volume of 25pl. To each dilution was added 25p 
1 of Tween 80/ether-treated influenza virus (A/Equi/2/Sussex/89) diluted to 4 HAU (see 
2.2.8). After 30 minutes at room temperature, 50pl of a 1% suspension of RBC were 
added to each well. The plates were then incubated for 30 minutes at room temperature. 
The HI titre of each serum/nasal wash was read to be the reciprocal of the highest dilution 
causing inhibition of the haemagglutination reaction (indicated by the ability of the RBC 
to run to the bottom of the well when the plate was tilted to an angle of 70°).
2.2.10 Influenza virus neutralisation assay in tissue culture
In a 96 well plate, oriented so that it had 8 columns and 12 rows, a half log titration of 
virus was set up beginning in row 1 (1:50 dilution). The virus used was 
A\Equi\2\Sussex\89, first isolated and passaged thrice in fertile hens eggs, which had 
subsequently been tissue-culture adapted by 10 low dilution passages in Madin Derby 
Canine Kidney (MDCK) cells [Imperial Laboratories, NBL-2(MDCK)].
Into this virus dilution series an equal volume of either serum free medium 199 ([Sigma, 
cat.no. M-0J48], containing 125 pg/ml of trypsin [Sigma, cat.no. T-89I8], 2 mM/ml L- 
glutamine [ICN Flow, cat. no. 10-801-49], 100 lU/ml penicillin [ICNFlow cat. no. 16-702- 
49], 100 pg/ml streptomycin [ICNFlow, cat. no.16-702-49] and 1% v/v of 7.5% sodium 
bicarbonate solution [ICN Flow, cat. no.l6-883-49](), or a nasal wash sample was added to
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all the wells of one set (in replicates of 4). The plates are then incubated for 1 hour at 37° 
C. Nasal wash samples were concentrated x3 using aquacide II [Calbiochem, cat. no.
17851] and sterilised through a 0.22pm filter prior to use.
MDCK cells were grown until confluent in 96 well flat bottomed tissue culture plates 
containing minimal essential medium (MEM [ICN Flow, cat. no.12-102-54] containing 
10% foetal calf serum [Sigma cat. no. F-2442], 2 mM/ml L-glutamine [ICN Flow, cat. 
no. 10-801-49], 100 lU/ml penicillin [ICNFlow cat. no.16-702-49], 100 pg/ml 
streptomycin [ICNFlow, cat. no.16-702-49], 1% v/v x 100 non-essential amino acids [ICN 
flow, cat.no. 16-810-49] and 1% v/v of 7.5% sodium bicarbonate solution [ICNFlow, cat. 
no.l6-883-49'\). The plates were then washed twice in sterile PBS. Using a multi-channel 
pipette, 1 0 0  pi of the virus dilutions were transferred fix>m the dilution plate into the 
corresponding wells containing MDCK cells and the plates were incubated for 1 hour at 
37°C. The plates were then aspirated and washed twice with sterile PBS. 100 pi of serum 
fi-ee M l99 was then added to all wells and the plates incubated for 72 hours in 5% CO], at 
37°C.
After the incubation period, the plates are centrifuged gently (50 xg, 2 mins), and virus 
was detected by its haemagglutination (HA) activity, performed on aliquots of supernatant 
aspirated from each well. The TCID50 per ml of the virus, used as a reference control, was 
read from the set of virus titration containing virus and Ml 99 only. The result was 
calculated using the Karber formula (Dougherty, 1964). The sets of virus titrations 
containing influenza neutralising antibody will give an apparent TCID50 which is less than 
that of the reference control. The apparent TCID50 of the antibody neutralised virus is 
subtracted from the TCID50 of the reference control to give a neutralisation index (NI).
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2.2.11 Protein assay
The protein concentration of nasal wash samples was determined using a commercially 
available kit [Bio-Rad, cat. no. 500-0006], by comparison with a standard curve of ESA. 
This method is based on the Bradford protein assay and was performed according to 
manufacturer's recommendations.
2.3 Results
2.3.1 Nasal wash immunoglobulins measured by ELISA
Nasal washes were taken during an intranasal vaccination study (described in 5.2). In this 
study three ponies (A58, D70, and 26E) received three doses of an intranasal 
CTB/influenza based vaccine before going onto an experimental infection. The results 
displayed in figures 2 .1  and 2 .2  indicate day 0  to be the day of the third application of 
vaccine, this day was 35 and 31 weeks after the first and second application of vaccine 
respectively. The animals were challenged using a technique described in Mumford et al., 
1990; briefly, 20ml of a dilution of influenza virus containing hens egg allantoic fluid was 
nebulised into a sealed room such that the ponies were exposed tolO* times a 
predetermined minimal infectious dose of influenza virus. A control pony, 001, received 
CTB alone on the same days as the vaccinates. Ponies P I6  and P I8 were the negative 
controls and received nothing at all.
Influenza specific antibody (IgA and IgG) present in the nasal washes was determined by 
ELISA (for method see 2.2.3), and expressed as a fimction of the mean of the group day 0
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Figure 2.1 Raw influenza specific IgA and IgG in nasal washes after vaccination and 
infection.
Figure 2.1 follows the increases in influenza specific IgA (graph A) and IgG (graph B) in 
nasal washes after intranasal vaccination (day 0 , open arrow) and experimental infection 
(day 2 2 , closed arrow).
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Figure 2.2 Flux of measured characteristics of nasal washes over the course of 
vaccination and infection.
Figure 2.2, graph A shows the levels of total immunoglobulin (Ab.490nm) found in nasal 
washes after vaccination (day 0 , open arrow) and infection (day 2 2 , closed arrow).
Graph B shows the concentration of protein (pg/ml) found in nasal washes after 
vaccination (day 0 , open arrow) and infection (day 2 2 , closed arrow).
Graph C shows the concentrations of equine serum albumin (ESA, pg/ml) found in nasal 
washes after vaccination (day 0 , open arrow) and infection (day 2 2 , closed arrow).
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Influenza specific antibody in BAL samples, taken 14 days after challenge, was 
measured by ELISA. The levels of ESA in these BAL samples were assayed and the 
influenza specific ELISA data divided by the concentrations of ESA, to give an arbitrary 
unit of influenza specific antibody per microgram ESA (data not shown). The ratio of 
mfluenza specific IgGiIgA in the BAL sample was significantly greater than that found in 
the nasal secretions (p<0.001). The change in ratio was predominantly because of an 
increase in absolute levels of influenza specific IgG present in the BAL and a 
concomitant, but smaller decrease in influenza specific IgA. The mean ratio of influenza 
specific IgGiIgA in the BAL samples was 4.4 (SD = 0.987), and in the nasal wash 1.317 
(SD = 0.46).
The amounts of total immunoglobulin (see 2.2.6), ESA (see 2.2.7), and total protein (see 
2.2.11) were also determined (see figure 2.2). A discussion of the flux of total protein and 
ESA after vaccination and challenge can be found in 2.3.4 Analysis o f  results. Briefly, the 
levels of both total protein and ESA remained relatively constant over the course of 
vaccination, whereupon, large increases could be observed after infection, presumably 
because of epithelial pathological events.
i .1
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Total levels of IgA and IgG were assayed by ELISA (for methods see 2.2.4 and 2.2.5, for 
results see 2.3.4 Analysis o f  results and figure 2.3). Briefly, vaccination and challenge had 
profound effects on the levels of total IgA and IgG present in the nasal washes. After 
vaccination there was a general increase in total levels of both isotypes and after challenge 
a transient reduction in total Ig-isotypes was observed.
2.3.2 Virus neutralisation activity o f nasal washes in tissue culture.
The virus neutralisation activity of the nasal washes taken after vaccination and infection 
were determined (see 2.2.10). The results indicate that the intranasally vaccinated 
individuals (A58, D70 and 26E) had little or no virus neutralising antibody in their 
nasopharynx before challenge. Fifteen days after challenge, the amount of virus- 
neutralising antibody in nasal wash of A58 was similar to that found in the previously 
infected ponies, P16 and P18.
Table 2.1.1, Virus-neutralisation activity of nasal wash (expressed as a Neutralisation 
Index)
Pony Vaccinated Day 0 Challenge
-1
Challenge
+15
Challenge
+42
A58 + 0 ND 2.25 ND
D70 + 0.4 -0.125 0.625 ND
26E + ND 0.325 1.5 1.5
P I6 - ND ND 2.375 ND
P18 - ND ND 2.625 ND
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Footnote: Assays to measure Neutralisation indices (NI) of nasal washes were developed 
during the course of this experiment and were considered to be a measure of the biological 
function of the vaccine or infection induced nasopharyngeal antibody (NI = TCIDso of a 
stock virus - apparent TCID50 of the stock virus preincubated with nasal wash, for method 
see 2 .2 .10)
2.3.3 Haemagglutination activity o f nasal washes
Nasal washes taken after infection were shown to inhibit virus-induced haemagglutination 
of chicken red blood cells. The HI titres expressed as log 2 showed a strong correlation 
(r=0.8851 ) with virus neutralisation activity in vitro (figure 2.4).
2.3.4 Analysis o f results section
This study provides an excellent example of why the nasal wash standardisation 
techniques are crucial for accurate interpretation of nasal wash ELISA data. Examination 
of the raw nasal wash influenza specific ELISA data (figure 2.1) would suggest that the 
three ponies, that were vaccinated with CTB/S89, had detectable levels of influenza 
specific IgA at the time of challenge. Moreover, the pony 001, >\diich had been vaccinated 
with CTB alone also had significant levels of influenza specific antibody in its nasal 
secretions. This evidence is contradictory to the observation that no VN antibody could be 
detected in these samples and the fact that all ponies became infected after experimental 
challenge. Ideally the parameter which is used to standardise the nasal wash data would be 
an easily measurable feature which remains relatively constant over the time course of an 
experiment, and whose flux are shared in both vaccinates and control animals.
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Figure 2.3 Flux of isotype specific immunoglobulin in nasal washes over the course of 
vaccination and infection.
Figure 2,3 shows the levels of total IgA (graph A) and IgG (graph B) in nasal washes after 
vaccination (day 0, open arrow) and infection (day 22, closed arrow).
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In an attempt to negate the variability of nasal secretion dilution during the nasal wash 
procedure, and therefore its influence on the raw ELISA data, three methods of 
standardisation were used. These methods will be discussed, in turn, below.
A) Standardisation using ESA
A competition ELISA was developed to measure the concentrations of equine serum 
albumin (ESA) present in nasal washes (for method see 2.2.7). The concentration of ESA 
was determined for each nasal wash (figure 2.2, graph C). By dividing the raw influenza 
specific ELISA data by the concentration of ESA present in the nasal wash, an arbitrary 
unit for influenza specific antibody (Ab.490nm) per microgram ESA in the nasal wash 
was calculated (Figure 2.5).
The levels of ESA in nasal washes during the course of the vaccinations remained very 
low, at the limit of detection, in certain animals after infection, however, these levels 
increased dramatically (figure 2.2, graph C). This could be explained by the pathology of 
the influenza virus, causing damage of the epithelium of the nasopharynx, and thereby 
allowing ESA to leak directly from the circulation into the nasopharynx. Moreover, when 
the ESA data was used to standardise the influenza specific data from our four animals, 
the pony which had received CTB alone showed the highest level of influenza specific 
antibody of the group. This level was equivalent to that seen in the control animals 14 
days after infection.
Therefore, where comparisons between nasal washes taken fix)m protected and infected 
animals are necessary, the use of ESA as a parameter to standardise nasal washes would 
lead to inaccurate conclusions.
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B) Standardisation by protein concentration
The protein concentration of each nasal wash was determined as described in 2.2.11 
(figure 2.2, graph B). By dividing the raw influenza specific ELISA data by the protein 
concentration of each nasal wash, an arbitrary unit for influenza specific antibody 
(Ab.490nm) per microgram of total protein present in the nasal wash was calculated 
(figure 2 .6 ).
The measurement of total protein in each nasal wash is very easy and may only suffer 
fi-om the sensitivity of the Bio-Rad assay itself. The data shown in figure 2.2, graph B, 
show a large inter-pony variation. Once this data has been used to standardise the 
influenza specific ELISA data (figure 2.6), it is clear to see that according to this method 
no pony had any influenza specific immunoglobulin in their nasal secretions at the time of 
challenge.
The standardisation method using total ESA (see above), and total protein, do not take 
into account the fact that after challenge any leakage of systenüc immunoglobulin into the 
nasopharynx would be of a predominantly IgG isotype. Any effect on the influenza 
specific IgA data would therefore be misleading.
To take one pony as an example, pony D70 had the largest increase in ESA after 
challenge. This pony also had the largest increase in total protein after challenge (figure
2.2). D70 also had a very large rise in total IgG present in the nasal wash (figure 2.3). 
However, the level of total IgA in the nasal wash did not increase so dramatically (figure
2.3). It seems, therefore, that standardisation of nasal wash influenza specific IgA data 
with the levels of total IgA would not be sensitive to leakage of systemic protein after 
challenge.
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Figure 2.4 Relationship between nasal wash virus neutralisation (VN) and 
haemagglutination inhibition (HI) activity.
Figure 2.4 shows the correlation of VN and ffl activity of nasal washes. Open circles 
represent an individual nasal wash taken before or after infection, r = correlation 
coefficient.
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Figure 2.5 Influenza specific immunoglobulin in nasal washes expressed as a function
of total equine serum albumin.
Figure 2.5 shows the changes in influenza specific IgA (graph A) and IgG (graph B) in 
nasal washes after vaccination (day 0 , open arrow) and infection (day 2 2 , closed arrow). 
Data expressed as raw influenza specific ELISA data (Ab.490nm) fi-om a nasal wash -r 
concentration of ESA in the nasal wash (|xg/ml).
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Figure 2.6 Influenza specific immunoglobulin in nasal washes expressed as a function
of total protein.
Figure 2.6 shows the changes in influenza specific IgA (graph A) and IgG (graph B) in 
nasal washes after vaccination (day 0 , open arrow) and infection (day 2 2 , closed arrow). 
Data expressed as raw influenza specific ELISA data (Ab.490nm) from a nasal wash -r 
concentration of protein in the nasal wash (pg/ml).
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Figure 2.7 Influenza specific immunoglobulin in nasal washes expressed as a function
of total isotype present in the nasal wash.
Figure 2.7 shows the changes in influenza specific IgA and IgG in nasal washes after 
vaccination (day 0, open arrow) and infection (day 22, closed arrow). Data expressed as 
raw influenza specific ELISA data (Ab.490nm) fi-om a nasal wash -s- total isotype present 
in the nasal wash (Ab.490nm).
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C) Standardisation by total immunoglobulin isotype
A capture ELISA was also developed to measure levels of isotype specific total 
immunoglobulin in the nasal washes (figure 2.3), as described in 2.2.4 and 2.2.5. The raw 
influenza specific ELISA data (Ab.490nm) for each immunoglobulin isotype, was divided 
by the capture ELISA data (Ab.490nm) for the total levels of that isotype present in the 
nasal wash (see figure 2.7, graphs A to D). The resultant figure was an arbitrary unit 
which expressed the levels of influenza specific antibody in relation to the levels total 
nasal wash antibody.
Figure 2.7, graphs A to D, show the influenza specific IgA and IgG expressed as a 
function of total immunoglobulin isotype. The levels of IgA and IgG do not remain 
constant over the course of a vaccination/challenge experiment (figure 2.3) and as such 
their use to standardise the influenza specific data is always going to be a compromise. 
The main advantage that it does have, however, is the low intra-animal variation and the 
insensitivity of the total IgA levels to the influx of systemic protein after an experimental 
infection.
2.4 Summary
Techniques have been developed, as described in this chapter, to measure the antibody 
responses induced in nasal secretions by vaccination or infection. It has been shown to be 
vital, that influenza specific ELISA data is standardised to some definable parameter, in 
order that accurate interpretation is possible.
We have identified that influenza specific ELISA data is best expressed as a function of 
the total nasal wash antibody of that specific isotype (influenza specific ELISA data 
(Ab.490nm) / total isotype ELISA data (Ab.490nm)). This method was, therefore,
71
used during the remainder of this study.
Nasal wash immunoglobulin has been shown to have functional activity, and the methods 
to measure this have been developed. After infection, influenza specific ^tibodies show 
both haemagglutination inhibition and virus neutralisation activity in vitro.
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Chapter 3
Measurement of B cell traffic
Measurement of B cell traffic
3.1.1 Introduction
During the early 1980% the development of established solid phase immunoenzymatic 
assays allowed the enumeration of specific antibody secreting cells (Czerkinsky et al., 
1983; Sedgwick and Holt, 1983). This technique, termed ELISPOT, has developed 
through the years to include assays to measure not only antibody secreting cells (ASC) but 
also other cell secreted products such as cytokines (Hutchings et al., 1989). In a manner 
similar to other enzyme-linked immunosorbant assays (ELISA) the ELISPOT is 
commonly performed in multi-well plates. By the use of an insoluble chromagen, the end 
result is an enumeration of cells that secrete a specific product rather than a measure of the 
concentration of the product (see figure 3.1 for schematic presentation of the technique).
3.1.2 The use o f ELISPOT to measure mucosal immunity
Amongst its many uses, this technique has been utilised to measure the stimulation of the 
common mucosal immune system (CMIS, see chapter 1). According to the hypothesis of 
the CMIS, afier a mucosal application of an antigen a stimulation of local B cells will 
occur. Clonal proliferation of these cells will take place in the local lymph nodes before 
entering the blood stream to traffic to distant mucosal effector sites (for extensive review 
see Phillips-Quagliata and Lamm, 1994). After mucosal vaccination or infection, 
ELISPOT assays are used to detect the appearance of antigen specific, antibody secreting 
B cells within the peripheral blood mononuclear cells (PBMC).
73
Circumstantial evidence to support the association between the trafficking ASC and the 
CMIS is the apparent temporal relationship between the appearance of antigen specific 
ASC in the blood, their later arrival at other distant effector sites, and the appearance of 
antigen specific immunoglobulins in the external secretions (Czerkinsky et aL, 1991 ; 
Moldoveanu et al., 1995). However, the first solid evidence has only recently become 
available and this evidence revolved around the study of homing receptor expression on 
the surface of the ASC. Address markers dedicated to mucosal sites have been identified. 
In man one such receptor is MAdCAM-1, with its corresponding lymphocyte-expressed 
ligand, the integrin a4p7 (Kilshaw and Murant, 1991; Hu e/ al., 1992; Berlin et al., 1993; 
Erie et al., 1994; Hamann et al., 1994; Viney et al., 1996). The integrin a4p7 has been 
shown to mediate binding to Peyers patch high endothelial venules (HEV), but not 
peripheral lymph node HEV (Berlin et al., 1993).
Quiding et al. (1995) demonstrated differences in the ASC responses derived fi’om oral 
vaccination with cholera toxin B chain (CTB)> and those derived fi’om a systemic 
vaccination with tetanus toxoid (TT). Almost all of the TT specific ASC expressed L- 
selectin, a marker mediating homing to peripheral lymph nodes (Kushimoto et al., 1990; 
Kansas, 1992), whereas only 40% of CTB specific ASC expressed this receptor. Kantele 
et al. (1996) further observed differences in patients with ongoing gastrointestinal 
infection. They observed an increased expression of a4p7 on peripheral blood pathogen- 
specific ASC compared to the ASC of healthy controls, and a concomitant reduction in L- 
selectin expression.
3.1.3 The application o f ELISPOT assays after vaccination and infection
ELISPOT assays have been utilised by many authors to investigate a wide variety of 
diseases and vaccines (for a recent review see Arvilommi, 1996). After an infection the
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ELISPOT assay typically reveals pathogen-specific ASC in the peripheral blood from 
days 4-5, peaking at around day 7, and disappearing in around 2-4 weeks (Arvilommi, 
1996). The ASC generally disappear from the blood only after the disappearance of the 
pathogen and the resolution of clinical signs.
Peripheral blood ASC have been reported after bacterial gastrointestinal, urinogenitory 
and respiratory infections (respectively: Kantele et al., 1988; Kantele et al., 1994; 
Nieminen et al., 1996). Few studies have investigated the ASC responses after viral 
infections. Mâkelâ et al. (1995) investigated army volunteers with acute upper respiratory 
tract infections including adeno- or influenza viruses. ASC specific for either pathogen 
could be detected by ELISPOT in the blood of the patient at clinical presentation. The 
numbers of ASC rapidly declined over time and were down to almost undetectable levels 
by 4 weeks after initial presentation. It is interesting to note that IgG was the dominant 
isotype of immunoglobulin to be produced, and that the numbers of ASC were not 
demonstrably linked to the titres of virus specific IgG in the convalescent serum.
According to its status as the most vigorously investigated mucosal adjuvant, cholera 
toxin (CT) has been used by many authors to investigate B cell responses after mucosal 
vaccination. In both mice and man, ASC responses are induced after oral or intranasal 
application of CT (Chen and Strober, 1990; Lewis et al., 1991; Jertbom et al., 1994; 
Quiding et al., 1995; Czerkinsky et al., 1991). These ASC appear in the peripheral blood 
of humans 7 days after oral vaccination, with roughly equal frequencies of IgG and IgA 
secreting cells (around 80 ASC/10^ PBMC, Quiding el al., 1995).
ASC specific for both CT and bystander antigens have been detected in peripheral blood 
after oral (Jackson et al., 1993; Quiding et a i, 1995) and intranasal (Wu and Russell, 
1993; Russell et a i, 1996) application of the CT adjuvanted vaccine. CT specific ASC
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derived from oral vaccination of humans exhibit "mucosal" B cell phenotypes, and 
therefore favour the population of mucosal effector sites (Quiding et al., 1995). Russell 
and colleagues (1996) provided further evidence for the mucosal "destiny" of circulating 
ASC by inducing antigen specific IgA in mucosal secretions in the absence of IgA in the 
serum. Intranasal vaccination of rhesus monkeys with CTB together with bacterial antigen 
(Ag I/II), induces Ag I/II specific antibodies in serum, saliva, faecal and genital samples. 
ASC specific for Ag I/II, mainly of the IgA isotype, were found in the peripheral blood 1 
week after vaccination. The resulting antibodies, IgA and IgG, present in nasal and 
vaginal washes may not have been derived from the same cellular source. Nasal IgG 
showed a strong correlation with serum IgG, and therefore may have been derived by 
transudation from the circulation. In contrast, nasal IgA, and both vaginal IgA and IgG, 
did not correlate with plasma antibody responses, suggesting a contribution of local 
synthesis (Russell et al., 1996).
The experimental evidence supports the thesis that ASC derived by mucosal vaccination 
express homing receptors favouring the mucosae. Also, antigen specific immunoglobulins 
may be induced in external secretions in the absence of antigen specific antibody in the 
circulation. Taken together these findings support the idea that circulating ASC observed 
after mucosal vaccination reflect the induction of mucosal immunity.
The aim of this study is to develop an ELISPOT assay for use in the equine system and 
apply it to the study of B cell responses after mucosal vaccination and infection. This 
technique will be used to verify immunological stimulation, and by implication provide 
evidence for the existance of a CMIS in the horse.
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3.2 Materials and Methods
3.2.1 Animal Work 
Intranasal vaccination
It was previously determined that horses tolerated an intranasal application of CTB (100 p 
g [Sigma cat.no.C‘9903]), in terms of absence of pyrexia and other clinical signs. Ponies 
that were to receive the vaccine were sedated using 0.2 ml of intravenous Domosedan 
[Veterinary drug company]. 50 pg of CTB was instilled into both nasal passages using 
either of the two techniques described in chapter 4. Rectal temperatures were taken, the 
ponies were kept in boxes and observed at regular time periods up to 24 hours after 
application. Ponies recieved two applications of CTB, one "priming" dose and another 3-4 
weeks later. Over the time course of the experiment heparinised blood samples (for 
ELISPOT assay, see 3.2.2), serum and nasal wash (see 2.2.1) samples were taken for later 
analysis.
Influenza challenge
Ponies with low, or absent, serum influenza specific serum antibody (HI) were selected to 
go onto influenza challenge. These animals were experimentally infected by exposure to 
infectious aerosol as described by Mumford et al. (1990). Briefly, after an isolation of 
influenza virus from a field outbreak of equine influenza in 1989, A/Equi/2/Sussex/89 
virus, as it became known, was passaged thrice in fertile hens eggs, as described in 
5.1.2.1. This large stock of challenge virus was diluted from 10° to 10*°, and used in an 
experimental infection, wherein nebulised virus was introduced to groups of ponies in a 
sealed challenge room, to determine the minimum infectious dose (MID). Subsequent
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experimental infections were performed using lO^xMID of the frozen stock of challenge 
virus, in the same challenge room.
Blood samples were taken by jugular venipuncture and nasal wash samples were taken 
(see 2 .2 .1) during the course of the infection.
3.2.2 Isolation o f PBMC
Blood samples were collected from ponies by jugular veinipuncture into 15 ml 
vaccutainers containing 225 units of sodium heparin ((Mucous) Heparin injection BP, [CP 
Pharmaceuticals, Wrexham, UK\). The red blood cells were allowed to settle and the 
PBMC rich plasma was loaded onto Ficoll-Paque [Pharmacia Biotech AB, Uppsala, 
Sweden, cat No. 17-0840-03] for density gradient centrifugation (30 min @ 275g, 22°C). 
PBMC were harvested from the interface between the plasma and Ficoll-Paque, and were 
washed twice, by centrifugation and resuspension (10 min @ 275g) in Hanks wash (Hanks 
balanced salt solution, without calcium or magnesium [ICNFlow, cat. no. 18-104-54], 
containing 200 lU/ml penicillin [ICNFlow cat. no.16-702-49], 200 pg/ml streptomycin 
[ICN Flow, cat. no. 16-702-49], and 5ml of a 7.5 % sodium bicarbonate solution [ICN 
Flow, cat. no. 16-883-49]). The PBMC were resuspended in complete RPMI (RPMI 1640 
[ICN Flow, cat. no. 12-602-54] containing 10% heat inactivated foetal calf serum [Sigma 
cat. no. F-2442], 2 mM/ml L-glutamine [ICN Flow, cat. no. 10-801-49], 100 lU/ml 
penicillin, 100 pg/ml streptomycin (cRPMI)), and were counted using a haemocytometer. 
The cell concentration was adjusted to 4 x10^ PBMC/ml cRPMI.
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3.2.3 ELISPOT assay
24 well tissue culture plates [Costar, Cambridge MA 02140, cat.no. 3524] were coated 
overnight, @ 4®C, with antigen (either cholera toxin B chain [Sigma, cat.no. C9903] 
influenza virus (see chapter 5))diluted to 50 |xg/ml in 0.05M coating buffer (carbonate- 
bicarbonate buffer pH9.6, [Sigma, cat.no. C-304I\). The plates were incubated for 1 hr @ 
37 °C in blocking buffer (phosphate buffered saline [Unipath Ltd, cat.no. BRI4], 
containing 0.05% Tween 20 [Sigma, cat.no. P-I379], and 2% dried skimmed milk 
[Biorad, cat.no. 170-6404]) to block all free sites. The plates were washed thrice with 
washing buffer (phosphate buffered saline [Unipath Ltd, cat.no. BRI4], containing 0.05% 
Tween 20 [Sigma, cat.no. P-I379\).
Cells were added, in triplicate, in 250 pi volumes. Each well contained either 5x10^ or Ix 
10^ PBMC. The plates were incubated overnight @ 37°C, 5% CO2  The plates were then 
washed vigorously with tap water and then thrice with washing buffer. The primary 
antibody was then added, affinity purified y-chain specific anti-equine IgG-biotin (1:500) 
[Dynatech, K&P, cat.no. 16-21-02] or monoclonal anti-equine IgA-biotin (K129-3E7, 
kindly donated by Professor Chris Stokes), 1:500) diluted in blocking buffer, and 
incubated for 1 V2 hours @ 37°C. The plates were washed thrice with washing buffer. 
Streptavidin-alkaline phosphatase (1:1000) [Sigma, cat.no. E-2636] diluted in blocking 
buffer was added and incubated for 1 hour @ 37°C. The plates were washed thrice in 
washing buffer. The insoluble chromagen 5-bromo-4-chloro-indolyl phosphate (BCIP 
[Sigma, cat.no. BI026], dissolved in AMP buffer (see appendix B) @ 100 mg/ml) was 
added and incubated @ 37°C until the spots became visible. The reaction was stopped 
with distilled water and the plates left to diy. The spots were enumerated using a stereo 
dissection microscope.
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3.2.4 ELISA assays for antibody quantification
ELISA assays were used to follow CTB and influenza specific immunoglobulins in either 
serum of nasal wash samples. Methods to determine total isotype specific immunglobulin 
present in nasal wash samples are given in 2.2.4 and 2.2.5. The influenza specific ELISA 
for both nasal wash and serum antibody were performed as described in 2.2.3.
Immunoglobulins present in serum and nasal washes specific for CTB were followed by 
ELISA. 96-well flat bottomed ELISA plates (Immunlon 3 [Dynatech cat.no. 011-010- 
5755]) were coated with 20 pg/ml CTB [Sigma cat.no.C-9903] diluted in coating buffer, 
and incubated overnight @ 4°C . All additions were in 100 pi volumes. The plate was 
incubated with blocking buffer for 1 hour @ 37®C. The plates were washed thrice with 
washing buffer. Serum samples were added at a dilution of 1:50 and titrated two-fold 
across the plate. Nasal wash samples were added neat and titrated two-fold across the 
plate. The samples were incubated for 1 hour @ 37®C. The plates were washed thrice in 
washing buffer and the anti-immunoglobulins were added, affinity purified y-chain 
specific anti-equine IgG-biotin (1:1000) [Dynotech, K&P, cat.no. 16-21-02] or 
monoclonal anti-equine IgA-biotin (clone 3E7,1:500) diluted in blocking buffer, and were 
incubated for 1 hour @ 37°C. The plates were washed thrice in washing buffer and 
streptavidin-horseradish. peroxidase, (1:1000 [Amersham, cat.no. RPN 1231\) diluted in 
blocking buffer, was added and incubated for 1 hour @ 37**C. The plates were washed 
thrice with washing buffer and the chromagen 0-phenyldiamine (OPD [Sigma, cat.no. 
P6912]) diluted to 0.5 mg/ml in phosphate-citrate buffer, with sodium perborate [Sigma, 
cat.no. P-4922], was added. After 20 minutes for the colour to develop the reaction was 
stopped, with 50 pl/well 4M H2 SO4 , and the absorbance read at 490 nm (Dynatech 
ELISA plate reader, DIAS system).
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Figure 3.1 Schematic representation of the ELISPOT technique.
a) Multi-well plates are coated with antigen.
b) A predetermined number of peripheral blood mononuclear cells (PBMC) are added to 
the wells and incubated overnight, 4°C.
c) The PBMC settle to the bottom of the well where they secrete their specific antibodies. 
Antigen specific immunoglobulins bind to the plate in the vicinity of their cell of origin.
d) All PBMC and non-specific immunoglobulins are washed off.
e) Anti-immunoglobulin conjugates are added and therefore mark the position of the 
antigen specific cell.
f) A chromagen is added and its insoluble product forms a spot which can be counted 
using a stereomicroscope.
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Figure 3 .2 Influenza specific ASC in the PBMC of ponies after experimental 
infection.
Figure 3.2 shows the numbers of influenza specific ASC in the circulation of five ponies 
after an experimental influenza infection (on day 0). Graph A shows the numbers of IgG 
producing ASC and Graph B shows the numbers of IgA producing ASC. Results are 
expressed as number of influenza specific ASC per 10^  PBMC. Nb, not all ponies were 
sampled at each time point:
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3.3 Results
3.3.1 Trafficking B cells after experimental influenza infection
ELISPOT assays were performed at various time points (up to 21 days) after an 
experimental influenza infection. All animals were considered "flu free" in terms of lack 
of influenza history (infection or vaccination), and absence of serum influenza specific 
antibody. The animals were challenged with influenza by aerosol on day 0. ASC specific 
for influenza appeared in the peripheral blood by day 7 after infection, peaked at around 
day 12, and then slowly declined by day 21 after infection (figure 3.2). ASC producing 
IgG were predominant with respect to IgA, showing a ratio of approximately 4:1. It 
should be noted that because of different ponies being challenged at different days not all 
animals were sampled on all of the time points shown in figure 3.2. This graph should be 
taken to show a general trend indicating the temporal appearence of influenza specific 
ASC in the peripheral blood of infected ponies.
3.3.2 Trafficking B cells after intranasal vaccination with CTB
Three ponies recieved two intranasal applications of CTB. The ASC responses in the 
peripheral blood were followed and related to the temporal appearence of CTB specific 
immunoglobulins in nasal secretions and serum. This vaccination protocol resulted in 
high levels of CTB specific antibody in nasal secretions (IgA) and serum (IgG) (figure
3.3). Very few CTB specific ASC appeared in the peripheral blood after the first priming 
dose. However, significant numbers of CTB specific ASC appeared 5 days after the 
intranasal boost. The numbers of ASC peaked at around day 8, and declined to low levels 
by day 21 after boosting. Again IgG was the predominant immunoglobulin isotype 
produced.
The appearence of CTB specific IgA ASC in the peripheral blood coincided with the 
appearence of CTB specific IgA in the nasal secretions. Very little CTB specific IgG
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Figure 3.3 Cholera toxin specific antibody responses in nasal wash and serum of one 
pony, after intranasal vaccination with cholera toxin B chain (CTB).
Figure 3.3 shows changes in CTB specific IgA and IgG in nasal wash (graph A), 
expressed as arbitrary units (raw CTB specific data Ab.490nm / total isotype Ab.490nm). 
Graph B, CTB specific IgA and IgG in serum expressed as raw ELISA data (Ab.490nm). 
Intranasal vaccination (with lOOpg CTB, with the nasooharyngeal applicator) was 
performed on days 0 and day 30 (open arrows).
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Figure 3 .4 Relationship between the appearance of CTB specific ASC in the 
peripheral blood and the appearance of CTB specific immunoglobulin in nasal 
washes.
Figure 3.4, shows the temporal relationship between the appearance of CTB specific ASC 
in the peripheral blood and the appearence of CTB specific IgA and IgG in nasal washes 
after an intranasal boosting application of CTB. Peak numbers of CTB specific ASC 
occured on days 7 and 8. The histograms are shown overlaying one another to emphasise 
the transient nature of the appearance of ASC in the peripheral blood.
Graph A, The appearance of CTB specific IgA ASC in the peripheral blood is represented 
by the histograms (showing the numbers of ASC/10^  PBMC, on the right hand axis), and 
the changes in CTB specific IgA in nasal washes (Ab.490nm ^ total IgA, on the left hand 
axis).
Graph B, The appearance of CTB specific IgG ASC in the peripheral blood is represented 
by the histograms (showing numbers of ASC/10^ PBMC, on the right hand axis), and the 
changes in CTB specific IgG in nasal washes (Ab.490nm -h total IgG, on the left hand axis).
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Figure 3.5 Relationship between the appearance of CTB specific ASC in the 
peripheral blood and the appearance of CTB specific immunoglobulin in serum.
Figure 3.5 shows the temporal relationship between the appearance of CTB specific ASC 
in the peripheral blood and the appearance of CTB specific IgA and IgG in serum after an 
intranasal boosting application of CTB. The peak of CTB specific ASC occured on days 7 
and 8. The histograms are shown overlaying one another to emphasise the transient nature 
of the appear ance of ASC in the peripheral blood.
Graph A, The appearance of CTB specific IgG ASC in the peripheral blood is represented 
by the histograms (showing numbers of CTB specific ASC/10^  PBMC, right hand axis), 
and the changes in CTB specific IgG in serirm (Ab.490nm, left hand axis).
Graph B, The appearance of CTB specific IgA ASC in the peripheral blood is represented 
by the histograms (showing number's of CTB specific ASC/10^ PBMC, right hand axis), 
and the changes in CTB specific IgA in ser-um (Ab.490nm, left hand axis).
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appeared in the nasal secretions despite very high numbers of CTB specific IgG ASC in 
the peripheral blood (figure 3.4). In contrast the appearence of CTB specific IgG ASC 
coincided with a sharp rise in CTB specific IgG in serum. No CTB specific IgA was foimd 
in the serum despite significant numbers of CTB specific IgA ASC in the PBMC (figure 
3.5).
3.4 Discussion
3.4.1 ASC responses in the peripheral blood after influenza infection
In common with other species, ASC specific for influenza virus have been detected in the 
peripheral blood of horses after infection. The numbers of ASC, and the isotype secretion 
profile, are in accord with those found after a human influenza infection (Mâkelâ et 
a/., 1995).
ELISA assays of nasal wash samples taken from horses after infection revealed that the 
ratio of influenza specific IgG (ELISA O.D.), to IgA (ELISA O.D.) was about 1. The ratio 
of IgG to IgA in bronchoalveolar lavage fluid (BALE), on the other hand, was about 4:1 
(see chapter 2). Therefore the ratio of influenza specific IgG : IgA in the BAL more 
closely reflected the ASC situation in the peripheral blood than that found in the upper 
respiratory tract.
The ratio of IgG : IgA producing plasma cells varies throughout the length of the equine 
respiratory tract, IgA predominates in the upper respiratory tract while IgG predominates 
in the lower airways (Mair et a l, 1988). It is therefore interesting to note that even though 
a large proportion of the total influenza specific ASC in the peripheral blood produce IgG,
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50% of the nasopharyngeal influenza specific antibody is of the IgA isotype. Conversely, 
in another mucosal effector site (ie, the lower airways) there is a similar proportion of IgG 
: IgA to that found in the peripheral blood ASC. It should be noted, however, that the lack 
of influenza specific IgG in the nasopharynx may be because of the non-existence of a 
transport pathway for locally produced IgG to enter the airway lumen, and not the fact that 
IgG producing ASC do not selectively locate to the URT. Furthermore, these conclusions 
depend on the hypothesis that the influenza specific IgG present in the BAL samples is 
locally produced and not simply a transudate directly from the peripheral blood.
These observations suggest the existence of a system of selective B-cell trafficking, 
whereby mucosally activated B-cells producing influenza specific IgA selectively 
populate the respiratory tract of the horse.
3.4.2 ASC responses in the peripheral blood after intranasal application o f  CTB
CTB specific ASC were detected in the peripheral blood of horses after intranasal 
vaccination. This finding is in agreement with other authors working in other species (see 
introduction 3.1.2).
As in the experiments following ASC after influenza infection, the immune responses 
after intranasal vaccination with CTB showed a stark difference between IgA and IgG 
responses. The data suggest that the IgA ASC detected in the peripheral blood, are 
selectively locating to the mucosal surfaces. The IgA appearing in nasal secretions is 
therefore most likely to be locally produced. The IgG ASC, on the other hand, seem to be 
restricted to producing their product in the serum only, or mucosal sites other than the
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nasopharynx. It will be interesting to investigate this further in order to elucidate the 
homing receptor expression on trafficking equine lymphocytes.
Intranasal vaccination with CTB induces trafficking IgA producing ASC which seem to 
be populating exclusively mucosal effector sites. The appearence of these ASC in the 
peripheral blood proceeds, or coincides with, the appearence of CTB specific antibodies in 
external secretions. The results of this study provide the first description of antigen 
specific ACS responses after mucosal vaccination in the horse. These observations support 
the hypothesis of the existence of a CMIS in the horse, and also emphasises the utility of 
ELISPOT assays to measure the stimulation of the mucosal immune system after mucosal 
vaccination. This method should have application for furthering reasearch knowledge on 
the trafficking signals for equine lymphocytes.
89
Chapter 4
Development of the nasopharyngeal
applicator
4. Development of a nasopharyngeal applicator.
4.1 Introduction
Many studies have been reported of intranasal vaccination regimes which purport to 
stimulate mucosal immune responses in the nasopharynx and/or the upper respiratory 
tract. It is common practice to vaccinate mice intranasally by instillation of relatively large 
volumes of liquid vaccine and on occasions this has resulted in asphyxiation (C. Elson, 
personal communication). Ideally, an intranasal vaccine should be administered in a small 
volume and make contact with all the putative mucosal induction sites, preferably in the 
form of a spray of fine droplets. Groups working in the human field have looked at 
efficient nasal spray applicators (Kuno-Sakai et al., 1994; Hashigucci et al., 1996). 
Fortunately, the horse has large nostrils and the nasopharynx is easilly accessible for the 
purpose of vaccination and nasal wash sampling.
Work by Tim Mair (1987) described the distribution of lymphoid follicles, the putative 
induction sites of the mucosal immune response, within the respiratory tract of the horse.
In brief, he showed isolated single follicles throughout the upper respiratory tract (URT) 
with large aggregations of follicles in the pharyngeal recess, nasopharynx (especially 
around the entrance to the auditory tube), and around the larynx. A mucosal vaccine in the 
horse must therefore be targetted towards these putative induction sites in order to attain 
the most efficient uptake of antigen.
Simple flexible plastic pasteur pipettes have been used in horses to instill infectious virus 
into the nostrils of horses (Harmant et al., 1993), and these were used as a method for 
intranasal vaccination at the beginning of this study. However, liquid was expelled from 
these pipettes as a jet rather than a spray and it was thought that maximum coverage of the
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nasopharynx would be difficult with this system. Therefore, a more targetted delivery 
system was devised which not only delivered the vaccine directly into the nasopharynx 
but also increased the coverage area.
4.2 Materials and Methods
4.2.1 Use o f the pas tuer pipette
The vaccine (approximately 500 pi) was sucked all the way into the bulb of a flexible fine 
tipped pasteur pipette (127-P406-000 Elkay Eireann, Costelloe, Co. Galway, Ireland). The 
end of the pipette was inserted 10 cm up one nostril of the horse {i.e. the entire length of 
the pipette, not including the bulb), and the bulb was squeezed in rapid succession untill 
the whole volume had been instilled.
4.2.2 Construction and use o f the nasopharyngeal applicator
The basis of the applicator is a spray-unit dissected from a ladies hairspray can. The spray- 
unit can be used from any aerosol based on a "rocker" type rather than a simple "button" 
type spray. By the use of this type of aerosol, the spray-unit can be carved to have a long 
thin tube.An experimental system was constructed by wedging the spray unit into the end 
of a short length (approximately 40cm) of clear PVC tubing (Portex, 6.5mm external 
diametre x 2.5 mm internal diametre). A one-way stopcock, fitted with male and female 
luer adaptors (Vygon 871.10, Benkat Instruments, Ilkeston), was attached to the other end 
of the tube (figure 4.1).
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Figure 4.1 The nasopharyngeal applicator.
Figure 4.1 shows the construction of the nasopharyngeal appicator. nb. the length of the 
tubing is not to scale.
A Preparation before use.
With the gas tap turned off (a) the syringe is compressed to create a reservoir of air under 
pressure (b). The vaccine is held within the tubing (c).
B Use o f nasopharyngeal applicator.
When the gas tap is turned to its on position (d) the compressed air is released and the 
vaccine is forced through the spray nozzle (e) and deposited into the nasopharynx in a mist
(f).
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To use the applicator, the spray-unit end of the applicator was held upright and a small 
volume of vaccine was instilled into the tube through the stopcock. The stopcock was then 
turned to its "o ff position. A 50 ml syringe, filled with air, was inserted into the female 
luer adapter of the stopcock and the applicator was then inserted into the nostril of the 
horse to the desired location (see below). By squeezing the syringe a small volume of air 
under pressure was created, which was released by opening the stopcock. This compressed 
air forced the vaccine through the spray-unit end of the tube. The stopcock was then 
turned "o ff and a second cycle of 50ml of air was performed to discharge the residual 
vaccine left in the tube.
By examination of postmortem material it was found that the best location to release the 
vaccine was at the distal part of the nasal cavity at the opening of the nasopharynx. The 
length that the applicator had to be inserted into the nasal cavity was calculated to be 4/5x 
the distance between the opening of the false nostril and the medial canthus of the eye.
4.2.3 Comparison o f old v.5. new methods
A comparison of the old pasteur pipette and new nasopharyngeal applicator was 
performed on two ponies which were to be euthanased for reasons unconnected with this 
study. 1% methyl violet aqueous solution was instilled into the nares of the animals ante- 
mortem, in order to observe the areas covered by each vaccination method. In one pony, 
two applications (each of SOOpI) of 1% methyl violet was squirted up each nostril using 
the pasteur pipette. Likewise, in another pony 2x 500pl of 1% methyl violet was sprayed 
into the nasal passages using the nasopharyngeal applicator. The ponies were then 
euthanased, the heads were removed and split para-sagitally to one side of the nasal sepum
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using a handsaw (Biro, model 3336). The nasal septum was removed from the bisected 
head and the mucosal surfaces were inspected for traces of dye.
4.3 Results
Pasteur Pipette method
Inspection of the mucosal surfaces revealed a stream of dye along the ventral nasal meatus 
and along the floor of the nasopharynx. A very small amount of dye was observed on the 
lateral edges of the epiglottis. No staining was observed at the entrance to the auditory 
tube or in the nasopharyngeal recess. A small quantity of dye flowed from the nares of the 
pony (figure 4.2).
Nasopharyngeal applicator method
After bisection, complete staining of the distal 3-5 cm of the ventral meatus was observed. 
There was complete staining of the entire nasopharynx, epiglottis and proximal arytenoid, 
with a little dye reaching the proximal laryngeal canal. Small spray droplets were seen on 
the proximal dorsal, middle, and ventral meatus. Dye completely covered the auditory 
tube opening and nasophar\ ngeal recess (figure 4.2).
No traces of dye were observed in the oropharyngeal tonsil or eosophagus using either 
method.
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Figure 4.2 A comparison of two methods of intranasal vaccination.
Figure 4.2 A, shows the extent of dye coverage when applied with the pasteur pipette 
method (as described in 4.3).
Figure 4.2 B, shows the extent of dye coverage when applied with the novel 
nasopharyngeal applicator (as described in 4.3)
AB
-
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4.4 Conclusion
It was concluded that the nasopharyngeal applicator gave not only a significantly greater 
area of coverage compared to the old pasteur pipette method, but also enhanced the 
targeting of the vaccine towards the putative induction sites. The acceptability of this 
method of vaccination was confirmed by demonstrating the apparatus to an equine 
practitioner (Mr Robert Allpress). The applicator was used successfully in non-halter- 
broken ponies without the use of systemic sedation and Mr Allpress agreed that the 
system could be used in practise.
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Chapter 5
Experimental chapter
Chapter 5. Experimental chapter
5.1 Comparison of vaccine preparations
5.1.1 Introduction
The realisation that CTB could be used as an adjuvant as an alternative to the toxic 
holotoxin stimulated many authors to construct various vaccine combinations which have 
met varying success. It has been used admixed with (Tamura et a l, 1988b; Russell et a l, 
1996), chemically (Liang et a l, 1989; Wu and Russell, 1993 and 1995; Russell et a l,
1996) or genetically (Hajishengallis et a l, 1995) conjugated to the vaccine antigen.
Chemical conjugation of antigen to cholera toxin affects the antigenicity of both 
components, and the GMl binding activity of the CTB (Liang et al., 1989). It was 
decided, therefore, to carry out a pilot study comparing the antigenic and immunogenic 
properties of 3 vaccine formulations, namely CTB/influenza conjugated using 
glutaraldehyde, CTB/influenza conjugated using 3-(2-pyridyldithio) proprionic acid 
succinimide ester (SPDP), and a simple mixture of CTB with influenza whole virus. These 
formulations were to be used to vaccinate three groups of ponies, each group containing 
naive and systemically primed animals, and the immunological responses assessed.
5.1.2 Materials and methods
5.1.2.1 Virus antigen preparation
Influenza virus (A/equi/2/Sussex/89) was grown in the allantoic cavity of 10 day old 
embryonated hens' eggs for 72 hours at 34°C. The eggs were placed at 4°C overnight prior
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to harvesting. The allantoic fluid was clarified by low speed centrifugation (1000 x g, 4' 
C) followed by high speed centrifugation to pellet the virus (2.5 hours at average g = 
29,500), 4°C). The resuspended pellet was then further purified by centrifugation on a 
discontinuous (15%, 30%, 60%) sucrose gradient at 4 °C for 1.5 hours at average g = 
51,850. Virus was collected from the 30%/60% interface and washed in sterile PBS. 
Protein concentration of the resulting virus stock was determined using the Micro BCA 
protein assay [Pierce, cat. no. 23235] after boiling for 4 minutes in PBS containing 1% 
SDS. Prior to use in the vaccine the correct concentration of virus stock was heat 
inactivated (h.i.) at 56°C for 1.5 hours. The h.i. virus was then passaged twice in 10 day 
old fertile hens eggs to verify the inactivation of the virus.
5.1.2.2 Conjugation o f CTB and influenza virus with glutaraldehyde
AÆqui/2/Sussex/89 influenza virus was adjusted to 2 mg/ml in PBS (containing ImM 
EDTA [Sigma, cat. no. E-9884]). An equal volume of the cross-linking reagent 
glutaraldehyde (40 mM, EM grade [Sigma, cat. no. G5882]), in PBS (containing ImM 
EDTA) was added and mixed for 18 hours at room temperature. The reaction mixture was 
dialysed against 2000 volumes of PBS (containing ImM EDTA). Cholera toxin B chain 
[Sigma, cat. no. C9903] was added at a ratio of 1:25 w/w, and incubated for 24 hours at 4° 
C. The conjugate was then dialysed against 2000 volumes of PBS (containing ImM 
EDTA), and o-lysine [Sigma, cat. no. L-5501] was added to a final concentration of 20 
mM. Conjugation of the proteins was evidenced by ELISA tests using GMI ganglioside to 
capture the conjugate and revealed by anti-influenza antibody. The final product was 
dialysed for 2 hours against 2000 volumes of PBS in a dialysis tubing with a 30,000 MW 
cut-off membrane, to purify the conjugate.
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5.1.2.3 Conjugation o f  CTB and influenza virus with SPDP
The conjugation procedure was performed with 3-(2-pyridyldithio) proprionic acid 
succinimide ester (SPDP) which incorporates a disulfide bridge between the two 
conjugated species, following manufacturers instructions [Pierce, cat. no. 21557]. Briefly, 
the two proteins were diluted to 2 mg/ml in borate buffered saline (BBS [Pierce, cat. no. 
28384]), and both separately treated with the SPDP stock reagent for 30 minutes at room 
temperature. The proteins were dialysed against 2000 volumes of BBS to remove excess 
reagent. The SPDP-CTB protein was reduced with dithiothreitol (DTT), and the SPDP 
derivatised influenza protein was mixed with the DTT-reduced CTB for 18 hours at room 
temperature. The conjugate was separated from low molecular reagents such as free SPDP 
and DTT by size exclusion chromatography on a Sephcryl® S-300 column. Evidence for 
conjugation was assessed as described in 5.1.2.2. The final product was dialysed for 2 
hours against 2000 volumes of PBS in a dialysis tubing with a 30,000 MW cut-off 
membrane, to purify the conjugate.
5.1.2.4 Animals and vaccination schedules
Three Welsh mountain ponies which had been infected 6 months previously, with 
A/equi/2/Sussex/89, and three naive 6 month old foals were used for intranasal 
vaccination. Three groups, each containing one naive foal and one previously infected 
pony, were vaccinated intranasally with either CTB/S89 mixture (containing lOOpg CTB 
and 300|ag heat inactivated S89; S89/CTB m ix.), CTB/S89 conjugated with 
glutaraldehyde (containing 300pg S89 and 12pg CTB, S89/CTB Glut.), or CTB/S89
99
conjugated with SPDP (containing 300pg S89 and 150|ig CTB, S89/CTB SPDP). The 
doses of S89 and CTB used in the two conjugates as described above were determined 
from the starting amounts used in the conjugation reaction procedure, and not from a 
product of the reaction procedure. For a summary of the vaccination protocols see table
5.1.1. The vaccines were administered on two occasions with an interval of 4 weeks 
between the vaccinations.
Table 5.1.1, Immunological status of ponies and vaccine formulations
Immunological state 
of the ponies
Vaccine formulation
S89/CTB Glut. S89/CTB SPDP S89/CTB mix
Naive D70 A58 26E
Previously infected A C D
Nasal wash and serum samples were taken periodically in order to follow the mucosal and 
systemic antibody responses.
5.1.3 Results
5.1.3.1 Nasopharyngeal influenza specific antibody
Intranasal vaccination with influenza virus and CTB induced influenza specific IgA in 
only 2 of the 6 ponies (figure 5.1.1, graph A), as detected by ELISA (see chapter 2.2.3). 
These ponies, D and C, were both previously infected and had received the CTB/S89 
mixture and CTB/S89 SPDP respectively. The results are shown as raw ELISA 
absorbence values. No increases in influenza specific nasopharyngeal IgG were observed 
(data not shown).
100
Figure 5.1.1 Antibody responses in response to intranasal vaccination with different 
CTB/S89 formulations.
Figure 5.1 describes the immunoglobulin responses to two intranasal applications of the 
CTB/S89 based formulations (as described in 5.1), on week 0 and 4 (open arrows).Graph 
A, shows the changes in influenza specific IgA in nasal washes expressed as raw ELISA 
data (Ab.490nm). Graph B shows the changes in CTB specific IgG in serum (Ab.490nm). 
Graph C shows the change in serum haemagglutination inhibition (HI) titre in serum 
(log:).
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5.1.3.2 Systemic CTB and influenza specific antibody
Serum CTB specific IgG, as measured by ELISA, was induced in two of the six ponies. 
These two ponies, D and 26E, both received the CTB/S89 mixture and showed an 
anamnestic response after the second booster application (figure 5.1.1, graph B). No 
serum CTB specific IgA was observed in any pony (data not shown).
Increases in influenza specific serum immunoglobulin, as measured by HI assay, were 
considered significant in only one pony, namely pony D. This pony had previously been 
infected with influenza and had received two applications of the CTB/S89 mixture (figure
5.1.1, graph C).
5.1.4 Conclusions
This set of experiments was concerned with identifying the optimum combination of CTB 
and influenza antigens. After examination of the data, by comparison of the magnitude of 
nasopharyngeal and systemic humoral responses, it was concluded that a mixture of the 
two components was superior to the CTB/S89 conjugation products.
The two conjugation procedures were selected from the literature as being suitable for 
conjugating influenza virus and CTB together. Glutaraldehyde is a well known cross- 
linking reagent, while SPDP because of its hetero-bifunctional nature was thought to 
cross-link the proteins in a more uniform controlled manner. Some preliminary studies 
(results not shown) were carried out to examine the conjugation of glutaraldehyde and 
SPDP, with a model antigen, bovine serum albumin (BSA). Each conjugate was shown to
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retain its GMl specific binding activity and antigenicity of both proteins as tested by 
ELISA (see table 5.1.2).
Table 5.1.2, GMl binding capacity of BSA-CTB conjugate as conjugated with the hetero­
bifunctional reagent SPDP.
Revealing antibody Antigen added to ELISA plate
CTB BSA BSA/CTB
Conjugate
a  CTB 0.7 0.04 0.65
a  BSA 0.05 0.05 0.64
Footnotes:
The ELISA plate was coated with GMl ganglioside, the three antigens (CTB, BSA, or the 
CTB/BSA conjugate) were added and allowed to bind to the G M l. After washing, the 
presence of antigen was revealed with either anti-CTB or anti-BSA antibodies. The table 
above shows the amounts of these antigens in ELISA absorbence values (Ab. 490nm).
Studies using 2D immuno-electrophoresis on these conjugates identified qualitative 
differences in the conjugates derived from the two methods tested. SPDP resulted in the 
generation of a uniform conjugate comprising BSA which was conjugated to one CTB 
chain. Glutaraldehyde conjugation, on the other hand, produced BSA conjugates of four 
distinct sizes, suggesting the inclusion of 1,2, 3, or 4 CTB chains (gels not shown).
Further ELISA studies using both GMl and anti-BSA capture elements suggested that 
when either conjugation method was used, approximately 66% of the total amount of BSA
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was successfully conjugated to CTB (data not shown). Given this suspicion that the 
S89/CTB conjugates may have contained free CTB, it is all the more surprising that the 
S89/CTB conjugates performed so poorly in the vaccination studies. Perhaps providing 
some indication that the conjugation conditions were sufficiently harsh to damage the 
antigenicity and adjuvanticity of the CTB.
Recent evidence has suggested that the immunogenicity of the CTB homologue, E. Coli 
heat-labile enterotoxin B subunit, may be a function of its GMl binding activity (Nashar 
et a i, 1996). However, the adjuvanticity of CTB has been suggested to be a consequence 
of trace impurities of whole CT (Tamura et al., 1994 and 1995). It has been shown that the 
glutaraldehye treatment of CT decreased both the activity of cholera toxin A chain and the 
GMl binding activity of the B chain (Liang et al., 1989). Despite this, glutaraldehyde and 
SPDP conjugates of CTB and antigen have been used successfully by several authors 
(Bessen and Fischetti, 1988; Liang et al., 1989).
However, it is interesting to note that in the experiments described here, the only two 
ponies to demonstrate a systemic CTB specific immune response, which was anamnestic 
after boosting, received the CTB/S89 mixture vaccine (figure 5.1.1, graph B). This is 
unlikely to be because of CTB dose as the SPDP-conjugated vaccines contained the 
highest dose of CTB, and therefore would further suggest that either the antigenicity or the 
adjuvanticity of the CTB was impaired during the conjugation process.
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5.2 Intranasal vaccination of naïve ponies.
5.2.1 Introduction
Intranasal vaccination of ponies, which had been previously infected with influenza, 
induced influenza specific IgA in the nasopharynx (as described in 5.1). The 6 month old 
“naive” group of animals, however, did not show any detectable mucosal antibody 
responses. It was decided that these three ponies, already twice intranasally vaccinated 
with a CTB/S89 based vaccine, would be boosted again this time with a simple mixture of 
CTB and influenza antigen. The animals were then experimentally infected and the 
clinical outcome to challenge investigated.
5.2.2 Methods
5.2.2.1 Animals and vaccination protocols
Three ponies, namely the previously naive animals used in the experiment in 5.1 (A58, 
D70, and 26E), having received two applications of the different vaccine preparations 
were vaccinated intranasally for a third time. The third application of vaccine was given 
35 weeks after the second intranasal vaccination, and was composed of a mixture of CTB 
(lOOpg) and heat inactivated A/Equi/2/Sussex/89 (300pg). The vaccinations were 
performed using the pasteur pipette method as described in 4.2.1. A fourth pony (pony 
001) received two applications, 4 weeks apart, of CTB (lOOpg) alone and was used as a 
negative control. Ponies P I6 and PI 8, were included in the challenge as further negative 
control animals and had received nothing at all.
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5.2.2.2 Pony sampling and challenge
After vaccination, nasal wash and serum samples were taken periodically to monitor 
mucosal and systemic antibody responses. All ponies were experimentally infected by 
exposure to a nebulised aerosol of infectious virus (A/equi/2/Sussex/89), as described by 
Mumford et al. (1990), 3 weeks after the final intranasal boosting. After challenge, nasal 
wash and serum samples were taken to monitor antibody responses, heparinised blood 
samples were taken and the isolated PBMC (see 3.2.2) were used in influenza specific 
ELISPOT assays (see 3.2.3).
5.2.3 Results
5.2.3.1 ELISA antibody responses
Two of the 3 ponies showed a slight, transient nasopharyngeal influenza specific antibody 
response to the third intranasal application of CTB/S89 based vaccine (figure 5.2.1). None 
of the ponies showed serum influenza specific IgG responses, as measured by ELISA, 
before or after the third intranasal vaccination. All vaccinated ponies showed little or no 
influenza specific antibody, in nasal washes or serum, at the time of challenge. A fourth 
pony which received CTB alone showed no influem^a specific antibody at any time after 
vaccination until the challenge (data not shown). After the experimental influenza 
infection all ponies showed marked increases in both serum and nasal wash influenza 
specific antibody (data expressed as arbitrai^ units AU, see chapter 2.5).
5.2.3.2 Nasal wash VN responses
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Nasal wash virus neutralisation (VN) activities were assayed in tissue culture (see 2.2.10). 
The three vaccinates did not show any VN activity on day 0 (day of third vaccination) of 
day 21 (challenge -1). However, VN antibody could be detected by day 15 and was still 
detectable up to 42 days after infection. Negative control ponies (PI 6  and PI 8 ) showed 
equivalent levels of VN antibody after infection as that observed in the vaccinated animals 
15 days post challenge.
Table 5.2.1, VN antibody measured in nasal washes before and after experimental 
infection (expressed as neutralisation indices, see 2 .2 .10).
Pony Vaccine
Day
Day 0 Challenge -1 Challenge +15 Challenge +42
A58 + 0 ND 2.25 ND
D70 + • 0.4 -0.125 0.625 ND
26E + ND 0.325 1.5 1.5
P16 - ND ND 2.375 ND
P18 - ND ND 2.625 ND
5.2.3.3 Protection from challenge
All ponies were challenged 21 days after the third vaccination. Briefly, none of the three 
vaccinated ponies were resistant to infection and showed typical signs of elevated rectal 
temperatures from day 2-9 post infection, dry cough, and mucopurulent nasal discharge. 
The pony that received CTB alone, and the negative control ponies that received nothing, 
all became infected with clinical signs of similar magnitude and duration (see table 5 .2 .2 ).
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Figure 5.2.1 Antibody responses to a third intranasal application of CTB/S89 based 
vaccine in naive ponies, and experimental infection.
Figure 5:2.1 shows the antibody responses in naive ponies vaccinated as described in 5.2. 
Day 0 corresponds to the final boosting vaccination prior to challenge, or week 35 in the 
vaccination schedule. Graph A shows the nasal wash influenza specific IgA and IgG 
(expressed as arbitrary units, as a fimction of total isotype), and IgG in serum (Ab.490nm), 
from pony A58. Graph B shows results fi*om pony 26 E, and graph C fi*om pony D70.
-O- Nasal wash IgA Nasal wash IgG -q - Serum IgG
1.2
oo
—  0.8
1 5 -
; - 0.6
-0 .4
5 -
- 0.2
I
I!
55o
%
Day
25-1 1.2
2 0 -
—  0.8
1 5 -
II —  0.6
1 0 -Vi
-0 .4
- 0.2
P
s (A
S’
%
Day
120 r - 1 . 2
100 -
80 — 0.8
II 6 0 - 0.6
4 0 - 0.4
2 0 - - 0.2
Day
108
Table 5.2.2 Clinical outcome from experimental infection of intranasally vaccinated naive 
ponies.
CTB alone A58 D70 26E
Day P C N P c N P c N P c N
0
1 -
2 + - + + + - + . _ +
3 ++ + + + + + ++ . + +
4 ++ + - ++ + + ++ • + 4 -
5 + + - - + + - H - +. + + . • 4 -
6 - + ++ -H - + + + + ++ ++ 4 - '  +
7 - + - -H - + + + + + + 4 -
8 - + - + + - ++ + . 4 -4 - 4 -
9 - - - + + - - +• . 4 -
10 - + - + - + _ 4 - 4 -4 -
11 - - + - - - - - - - - -
Footnotes:
Day = Day post challenge.
P = Pyrexia.
= Cough.
= Muco-purulent nasal discharge. 
= Mild clinical sign observed.
= Moderate clinical sign observed.
C
N
+
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5.2.3.4 Influenza specific ASC responses after infection
All ponies, vaccinates or controls, showed influenza specific antibody secreting cell 
responses (ASC) in the peripheral blood mononuclear cells (PBMC) after infection (figure 
5.2.2). These cells were detected in PBMC from day 5, reaching a peak at around day 12, 
after infection. There was a markedly greater number of influenza specific IgG ASC on 
days 11 and 12  in the intranasally vaccinated ponies as compared with the unvaccinated 
controls, or the pony which had vaccinated with CTB alone. There was no obvious 
difference in the influenza specific IgA producing ASC responses.
The surprisingly high responses seen in pony P I6  on day 11 after infection were unusual 
with respect to our previous experience with negative control ponies (n = 10).
Furthermore, on this day the “spots” were of an unusual nature in that they were very 
small, but still retained the diffuse edges, characteristic of ASC ELISPOTS.
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Figure 5.2.2 Influenza specific ASC in the peripheral blood after an experimental 
infection.
Figure 5.2.2 shows a comparison of the ASC responses in the PBMC after an infection 
between a group of negative control ponies (001, P16 and P18) and a group intranasally 
vaccinated naive ponies (as described in 5.2, D70, A58, and 26E).
Graph A, influenza specific IgG ASC in the intranasally vaccinated ponies.
Graph B, influenza specific IgA ASC in the intranasally vaccinated ponies.
Graph C, influenza specific IgG ASC in the negative control ponies.
Graph D, influenza specific IgA ASC in the negative control ponies.
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5.3 Intranasal vaccination of systemically primed ponies.
5.3.1 Introduction
The experience with the naive ponies showed that i.n. vaccination with inactivated 
influenza antigens, did not elicit a protective immunological response. The experiment 
described in 5.1 demonstrated that prior exposure to influenza virus was a requisite for a 
successful response to mucosal vaccination with CTB/S89. The contribution of systemic 
vaccination to the induction of mucosal immune responses after mucosal boosting has 
been the subject of a number of conflicting studies, and probably depends on factors such 
as host, antigen, and the use of a carrier. Studies in mice have demonstrated a requirement 
for systemic priming before mucosal boosting (Barzu et al., 1996), whilst others have 
demonstrated a preference for mucosal priming and boosting (Wu and Russell, 1994).
On the basis of these reports and the results of the studies described in 5.1 and 5.2, a third 
experiment was designed to investigate the role of systemic priming in the induction of 
mucosal immunological responses. A group of six yearlings, each without clinical and 
serological history of influenza infection were primed intramuscularly with conventional 
inactivated whole virus vaccine and then boosted intranasally. The immunological 
responses were monitored and the clinical outcome of an experimental infection was 
investigated.
5.3.2 Methods
5.3.2.1 Vaccination and sample protocols o f  the ponies
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Ponies which were to be systemically primed prior to intranasal boosting were vaccinated 
intramuscularly with 45pg of h.i. influenza virus (5.1.2.1) with alhydrogel® adjuvant 
[Superfos Biosector a/s, Denmark]. Although the concentration of haemagglutinin was not 
calculated, it was assumed to comprise approximately 30% of the total protein (from a 
review of the literature). Four and 8 weeks after priming, the animals were boosted by 
intranasal vaccination with 300pg of h.i. influenza virus, lOOpg of cholera toxin B chain 
[Sigma, cat. no. C9903], supplemented with 2pg of cholera toxin (whole molecule 
[Sigma, cat. no. C8052]). CT was added to the vaccine mixture because it has been shown 
to act synergistically as an adjuvant for nasal influenza vaccines (Tamura et al., 1994). 
Intranasal vaccination (i.n.) was performed with the nasopharyngeal applicator as 
described in chapter 4.2.2. Briefly, ponies that were to receive the vaccine were sedated 
using 0.2 ml of Domosedan [Veterinary Drug Company] intravenously. The vaccine was 
instilled in a total volume of 1 ml. Ponies were kept in a loose box overnight and observed 
at 2, 6 , and 24 hours after vaccination in case of any adverse reaction. The submandibular 
lymph nodes were palpated and rectal temperatures were taken at these time points.
Nasal wash samples (see chapter 2.2.1) were taken to monitor the appearance of mucosal 
immunoglobulins, and whole blood samples were collected by jugular venipuncture for 
measurement of circulating immunoglobulins and ELI SPOT assays (for methods of 
PBMC isolation and ELISPOT assays see 3.2.1 and 3.2.2 respectively).
A further two ponies (804 and B40) were intramuscularly primed and received no further 
vaccinations. Serum samples were taken from these ponies and the HI antibody 
monitored.
The six intranasally vaccinated ponies were experimentally infected by exposure to 
infectious aerosol, as described by Mumford et al. (1990), 3 weeks after the final
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intranasal boosting. Also included in the challenge were four negative control ponies with 
no clinical history of influenza infection or vaccination (V4, V7, V9, and V I4), and two 
positive controls that had been experimentally infected six months previously (40A and 
A51). These animals had recovered completely from their previous infection and were 
clinically normal. Previous studies have shown that nasal shedding of virus after 
experimental infection lasts for approximately 7 days. The positive control ponies were 
expected to be immune from rechallenge on the basis of previous studies carried out in 
this department (Hannant et al., 1988b).
5.3.2.2 Nasopharyngeal swabs and sample manipulation
Nasophamygeal swabs were taken, put into virus transport medium (VTM, PBS 
containing 2% tryptose phosphate broth [ICNFlow, cat. no. 16-821-49], 100 lU/ml 
penicillin [ICNFlow cat. no. 16-702-49], 100 pg/ml streptomycin [ICNFlow, cat. no.l6- 
702-49] and 5 pg/ml amphotericin B [Sigma, cat. no. A-2942] and placed on ice for 
transport to the laboratory. The swabs were squeezed using sterile forceps, the extracts 
clarified by centrifugation (1500xg, 5 mins), and aliquoted into sterile soda glass vials 
before freezing at -70°C.
5.3.2.3 Virus isolation from nasopharyngeal swab extracts
Nasopharyngeal swab extracts were thawed rapidly in a 37°C waterbath. 30|il of stock 
penicillin / streptomycin [10,000 lU/pg per ml, ICN Flow cat. no. 16-702-49, ICN Flow, 
cat. no. 16-702-49 respectively] was added to each 1 ml of extract to raise the antibiotic 
level to around 400 units/pg per ml. Dilutions of the extracts were prepared ranging from
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10® to 10"  ^ in logjo steps, in PBS containing 2% tryptose phosphate broth [ICNFlow, cat. 
no. 16-821-49] and 500 units/pg ml"  ^ penicillin and streptomycin [ICN Flow cat. no.l6- 
702-49, ICN Flow, cat. no. 16-702-49]. Nasal swab extracts were kept on wet ice until use. 
100 pi volumes of the titrated extracts were injected, in duplicate, into the allantoic cavity 
of 10 day old fertile hens' eggs. The eggs were incubated for 72 hours at 34°C, and then 
placed at 4°C overnight. Allantoic fluid was harvested from each individual egg and 
dilutions (neat, 1:2, and 1:4), of each harvested sample were prepared in V bottomed 96- 
well plates (in 25pl volumes). 25pl volumes of 1% chicken red blood cells were added to 
all wells and after 30 mins the plates were read for haemagglutination. The EID50 per ml 
of each swab extract was calculated using the Karber formula (Dougherty, 1964).
5.2.2.4 Detection o f  influenza virus nucleoprotein in the nasal swab extracts
Nucleoprotein (NP) of influenza virus was detected by a variation of the immunocapture 
ELISA as described by Cook et al. (1988). Briefly, NP present in the nasal swab extract 
was captured by polyclonal anti-equine influenza (H3N8) bound to the wells of a 96 well 
ELISA plate. The bound NP was then revealed using an anti NP monoclonal antibody 
labelled with horseradish peroxidase.
5.3.3 Results
5.3.3.1 HI antibody responses
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HI antibody was detected in the serum of all 6 of the vaccinated ponies after intramuscular 
vaccination. The intranasal boosting with CTB/S89 of primed ponies induced further 
increases in 5 of the 6 ponies (figures 5.3.1 to 5.3.6).
Intramuscular priming of ponies 804 and B40 induced transient but low amounts of serum 
HI antibody (figure 5.3.7). Log2 HI titre of 804 never increased above 3 and the maximum 
titre for pony B40 (5) was seen 54 days after priming. Ponies 804 and B40 did not 
progress to challenge for two reasons. Firstly, they did not become available for this 
experiment until the intranasal boosting procedures were well underway, and so it was not 
possible to examine their responses in parallel. Secondly, it was decided more important 
to measure the induction and decline of primary vaccination induced antibody in these 
ponies because there is sufficient published and laboratory data to show that ponies with 
HI titres of less than 6 are susceptible to infection (Hannant et a l, 1988a, 1988b, 1989a, 
1989b; Mumford et a l, 1983, 1988, 1990).
5.3.3.2 Virus neutralising antibody responses
The VN activity of nasal wash samples was investigated in tissue culture. At the time of 
challenge 4 of the 6 vaccinated ponies showed VN activity greater than those of the 
unvaccinated control animals 14 days after infection (figures 5.3.1 to 5.3 .6).
5.3.3.3 ELISPOT responses
After the first and second intranasal boosting vaccinations, significant numbers ( ^ 0  ASC 
per 10  ^PBMC, Nb, on day 0 no ASC were observed, the figure 20 was considered an 
arbitrary figure of significance) oflgA and IgG ASC were detected in 5 of the 6 ponies.
The ASC appeared in PBMC as early as 3-4 days after boosting, and peaked at day 5. The 
ASC responses following the second boost were not as great as that those seen after the 
first boosting vaccination (figures 5.3.1 to 5.3.6). The appearence of ASC coincided with
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Figure 5.3.1 Immunological responses of systemically primed ponies to intranasal
boosting with CTB/influenza vaccine, and experimental infection.
Data derived from a single pony : Pony F79
The nasopharyngeal and systemic antibody responses to intramuscular priming (day -28),
intranasal boosting vaccination with S89 and CTB (2%CT) on days 0 and 21, and
subsequent challenge with influenza virus (day 48).
= i.m.priming
^  = i.n.boosting 
^  = experimental challenge
- O  IgA >|< VN IgG
Panel A, Influenza specific nasopharyngeal IgA (O)and IgG ( • )  expressed as arbitrary
units (AU), as a function of total isotype, in relation to circulating influenza specific ASC,
illustrated as a histogram, showing numbers of ASC /10  ^PBMC.
□  IgG ASC g  IgA ASC
Panel B, Influenza specific nasopharyngeal IgA (O ) and IgG (# ) expressed as raw ELISA 
data, and virus neutralisation activity (assayed on day 0, 46, and 62) of the nasal washes 
(expressed as a neutralisation index (NI), asterisk sign).
Panel C, Serum IgA (O ) and IgG ( • )  (expressed as raw ELISA data, Ab.490nm) and
serum haemagglutination activity (expressed as histogram).
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Figure 5.3.2 Immunological responses of systemically primed ponies to intranasal
boosting with CTB/influenza vaccine, and experimental infection.
Data derived from a single pony: Pony 90F
The nasopharyngeal and systemic antibody responses to intramuscular priming (day -28),
intranasal boosting vaccination with S89 and CTB (2%CT) on days 0 and 21, and
subsequent challenge with influenza virus (day 48).
= i.m.priming
^  = i.n.boosting 
^  = experimental challenge
O  IgA >)< VN IgG
Panel A, Influenza specific nasopharyngeal IgA (O)and IgG ( • )  expressed as arbitrary
units (AU), as a function of total isotype, in relation to circulating influenza specific ASC,
illustrated as a histogram, showing numbers of ASC /lO^ PBMC.
□  IgG ASC g  IgA ASC
Panel B, Influenza specific nasopharyngeal IgA (O ) and IgG (#) expressed as raw ELISA 
data, and virus neutralisation activity (assayed on day 0, 46, and 62) of the nasal washes 
(expressed as a neutralisation index (NI), asterisk sign).
Panel C, Serum IgA (O ) and IgG ( • )  (expressed as raw ELISA data, Ab.490nm) and
serum haemagglutination activity (expressed as histogram).
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Figure 5 .3 .3 Immunological responses of systemically primed ponies to intranasal
boosting with CTB/influenza vaccine, and experimental infection.
Data derived from a single pony: Pony 6431
The nasopharyngeal and systemic antibody responses to intramuscular priming (day -28), 
intranasal boosting vaccination with S89 and CTB (2%CT) on days 0 and 21, and 
subsequent challenge with influenza virus (day 48).
^  = i.m.priming
^  = i.n.boosting 
^  = experimental challenge
-O- IgA >|< VN IgG
Panel A, Influenza specific nasopharyngeal IgA (O)and IgG ( • )  expressed as arbitrary
units (AU), as a function of total isotype, in relation to circulating influenza specific ASC,
illustrated as a histogram, showing numbers of ASC /lO* PBMC.
□  IgG ASC g  IgA ASC
Panel B, Influenza specific nasopharyngeal IgA (O) and IgG ( • )  expressed as raw ELISA 
data, and virus neutralisation activity (assayed on day 0, 46, and 62) of the nasal washes 
(expressed as a neutralisation index (NI), asterisk sign).
Panel C, Serum IgA (O ) and IgG ( • )  (expressed as raw ELISA data, Ab.490nm) and
serum haemagglutination activity (expressed as histogram).
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Figure 5.3.4 Immunological responses of systemically primed ponies to intranasal
boosting with CTB/influenza vaccine, and experimental infection.
Data derived from a single pony: Pony 1669
The nasopharyngeal and systemic antibody responses to intramuscular priming (day -28),
intranasal boosting vaccination with S89 and CTB (2%CT) on days 0 and 21, and
subsequent challenge with influenza virus (day 48).
= i.m.priming
^  = i.n.boosting 
^  = experimental challenge
-O- IgA >|< VN IgG
Panel A, Influenza specific nasopharyngeal IgA (O)and IgG ( • )  expressed as arbitrary
units (AU), as a function of total isotype, in relation to circulating influenza specific ASC,
illustrated as a histogram, showing numbers of ASC /10  ^PBMC.
□  IgG ASC g  IgA ASC
Panel B, Influenza specific nasopharyngeal IgA (O) and IgG (# ) expressed as raw ELISA 
data, and virus neutralisation activity (assayed on day 0, 46, and 62) of the nasal washes 
(expressed as a neutralisation index (NI), asterisk sign).
Panel C, Serum IgA (O ) and IgG ( • )  (expressed as raw ELISA data, Ab.490nm) and
serum haemagglutination activity (expressed as histogram).
1 0 0 ^
- 5 08 0 -
- 4 0
6 0 -
Oû 4 0 -
2 0 - -  10
3ZÜ
C
§
*oon
5
o
>œn
- 2 0  3
o3
00
2n
Day
ë i  ^  ■
o  0 .8  -O)
3 <
c ^ 0.6 -
Ë 2
- 5
- 4
c
0 .4 - - 3
0 .2 - - 2
2in
i
Io
3
9
Day
1 .2 - 1 I -  10
I :  0,.:
3
- 9
- 8
- 7
g .3 0.6 -
1 1  
E ^
I I 
^  0 0.2 -
- 6
0 .4 -
- 5
- 4
-20
i
o
%
Day
1 2 0
Figure 5.3.5 Immunological responses of systemically primed ponies to intranasal
boosting with CTB/influenza vaccine, and experimental infection.
Data derived from a single pony: Pony 04B
The nasopharyngeal and systemic antibody responses to intramuscular priming (day -28),
intranasal boosting vaccination with S89 and CTB (2%CT) on days 0 and 21, and
subsequent challenge with influenza virus (day 48).
^  = i.m.priming
^  = i.n.boosting 
^  = experimental challenge
- O  IgA >|< VN IgG
Panel A, Influenza specific nasopharyngeal IgA (O)and IgG ( • )  expressed as arbitrary
units (AU), as a function of total isotype, in relation to circulating influenza specific ASC,
illustrated as a histogram, showing numbers of ASC /10  ^PBMC.
□  IgG ASC g  IgA ASC
Panel B, Influenza specific nasopharyngeal IgA (O) and IgG (# ) expressed as raw ELISA 
data, and virus neutralisation activity (assayed on day 0, 46, and 62) of the nasal washes 
(expressed as a neutralisation index (NI), asterisk sign).
Panel C, Serum IgA (O ) and IgG (# )  (expressed as raw ELISA data, Ab.490nm) and
serum haemagglutination activity (expressed as histogram).
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Figure 5.3.6 Immunological responses of systemically primed ponies to intranasal
boosting with CTB/influenza vaccine, and experimental infection.
Data derived from a single pony: Pony C4D
The nasopharyngeal and systemic antibody responses to intramuscular priming (day -28), 
intranasal boosting vaccination with S89 and CTB (2%CT) on days 0 and 21, and 
subsequent challenge with influenza virus (day 48).
= i.m.priming
^  = i.n.boosting 
^  = experimental challenge
-O  IgA >|< VN IgG
Panel A, Influenza specific nasopharyngeal IgA (O)and IgG ( • )  expressed as arbitrary
units (AU), as a function of total isotype, in relation to circulating influenza specific ASC,
illustrated as a histogram, showing numbers of ASC 710  ^PBMC.
□  IgG ASC g  IgA ASC
Panel B, Influenza specific nasopharyngeal IgA (O ) and IgG ( • )  expressed as raw ELISA 
data, and virus neutralisation activity (assayed on day 0, 46, and 62) of the nasal washes 
(expressed as a neutralisation index (NI), asterisk sign).
Panel C, Serum IgA (O ) and IgG ( • )  (expressed as raw ELISA data, Ab.490nm) and
serum haemagglutination activity (expressed as histogram).
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Figure 5.3.7 Serum haemagglutination inhibition (HI) titres of intramuscularly 
primed ponies.
Figure 5.3.7 shows that serum HI titres in two control ponies at days 0, 7, 10, 24, 54, and 
67 after intramuscular priming with 45pg heat inactivated whole virus in Alhydrogel© 
adjuvant. The sensitivity of the HI assay with 4HAU per well is such that titres of less than 
3 (log]) cannot be registered. Therefore, a value of 2 (log]) should be taken to mean < 1/8 
including 0.
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or preceded the rise in influenza specific IgA (expressed in arbitrary units AU, see chapter 
2.5) in the nasal secretions in 4 of those 5 ponies (figures 5.3.1 to 5.3.6).
5.3.3.4 Antibody responses as measured by ELISA
Increases in influenza specific IgA were detected in the nasal washes of all 6 of the 
vaccinated ponies. However, no increases in nasal wash influenza specific IgG were 
detected. The virus neutralisation activity (NI) of the nasal washes closely mirrored the 
levels of influenza specific IgA (raw absorbence data) present in the nasal wash (figures
5.3.1 to 5.3.6; graph B). Serum influenza specific IgG was detected in all 6 of the 
vaccinates after the intramuscular priming, this was further boosted by the intranasal 
vaccinations in four of the six.
5.3.3.5 Response to challenge infection 
Unvaccinated control ponies
All 4 of the unvaccinated control ponies showed classical clinical signs of influenza 
infection after challenge (pyrexia, dry non-productive cough, ocular discharge, and 
mucopurulent nasal discharge, table 5.3.1).
Influenza specific ASC responses were detected in all 4 ponies, the kinetics of which 
seemed to be slower than those observed in the vaccinated pony group (figures 5.3.8 to 
5.3.11). Increases in nasal wash and serum influenza specific antibody were also observed 
in all ponies (figures 5.3.8 to 5.3.11). Also NP was detected in all ponies in 
nasopharyngeal swab
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Table 5.3.1 Clinical signs of the unvaccinated control ponies.
Figure 5.3.1 shows data derived from the experimental infection described in 5.3. The 
unvaccinated control ponies were scored for rectal temperatures (°F), cough, condition, 
ocular discharge, and nasal discharge. A sign designates the severity of the clinical 
sign.
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Table 5.3.2 Clinical signs of the vaccinated and previously infected ponies.
Figure 5.3.3 shows data derived from the experimental infection described in 5.3. The 
vaccinated (F79, 90F, 6431, 1669, 04B, C4D) and previously infected control ponies (A51 
and 40A) were scored for rectal temperatures (°F), cough, condition, ocular discharge, and 
nasal discharge. A sign designates the severity of the clinical sign.
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extracts from 2 to 8 days after infection. The levels of NP reflected the amount of live 
virus which was shed, as measured by titration in hens eggs (figure 5.3.14)
Previously infected ponies
As expected, (Hannant et a l, 1988b) the two ponies which had previously been infected 
with influenza were resistant to challenge infection (table 5.3.2). These ponies did not 
show NP in nasopharyngeal swab extracts and did not shed live virus (figure 5.3.14).
Influenza specific ASC responses were detected in both ponies (figures 5.3.12 and 5.3.13), 
Increases in nasal wash and serum immunoglobulins were also observed in both ponies 
(figures 5.3.12 and 5.3.13).
Vaccinates
All six intranasally boosted ponies were completely protected from influenza infection in 
that they did not exhibit any clinical signs (table 5.3.2) and did not show NP in nasal 
swab extracts or shed live virus (figure 5.3.14).
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Figure 5.3.8 Immunological responses of naive pony in response experimental
infection.
Data derived from a single pony: Pony V4
Figure 5.3.8 shows the nasopharyngeal and systemic antibody responses to an 
experimental infection.
^  = experimental challenge
-O- IgA >|< VN IgG
Graph A, Influenza specific nasopharyngeal IgA and IgG on the left hand axis (expressed 
as arbitrary units (AU), as a function of total isotype) in relation to circulating influenza 
specific ASC on the right hand axis (expressed as a histogram showing numbers of ASC 
/lO^PBMC).
□  IgG ASC H  IgA ASC
Graph B, Influenza specific nasopharyngeal IgA and IgG on the left hand axis(expressed 
as raw ELISA data, Ab.490nm) and virus neutralisation activity of the nasal washes on 
the right hand axis(expressed as a neutralisation index (NI), asterisk sign).
Graph C, Serum IgA and IgG on the left hand axis (expressed as raw ELISA data,
Ab.490nm) and serum haemagglutination activity on the right hand axis (expressed as a
histogram, log]).
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Figure 5.3.9 Immunological responses of naive pony in response experimental
infection.
Data derived from a single pony: Pony V7
Figure 5.3.9 shows the nasopharyngeal and systemic antibody responses to an 
experimental infection.
= e:q)erimental challenge
- O  IgA VN IgG
Graph A, Influenza specific nasopharyngeal IgA and IgG on the left hand axis (expressed
as arbitrary umts (AU), as a function of total isotype) in relation to circulating influenza
specific ASC on the right hand axis (numbers of ASC /lO* PBMC).
□  IgG ASC g  IgA ASC
Graph B, Influenza specific nasopharyngeal IgA and IgG on the left hand axis(expressed 
as raw ELISA data, Ab.490nm) and virus neutralisation activity of the nasal washes on 
the right hand axis(expressed as a neutralisation index (NI), asterisk sign).
Graph C, Serum IgA and IgG on the left hand axis (expressed as raw ELISA data, 
Ab.490nm) and serum haemagglutination activity on the right hand axis (expressed as a 
histogram, HI log]).
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Figure 5.3.10 Immunolo^cal responses of naive pony in response experimental
infection.
Data derived from a single pony: Pony V9
Figure 5.3.10 shows the nasopharyngeal and systemic antibody responses to an 
experimental infection.
^  = experimental challenge
-O- IgA >|( VN IgG
Graph A, Influenza specific nasopharyngeal IgA and IgG on the left hand axis (expressed 
as arbitrary units (AU), as a function of total isotype) in relation to circulating influenza 
specific ASC on the right hand axis (expressed as a histogram showing numbers of ASC 
/lO^PBMC).:
□  IgG ASC g  IgA ASC
Graph B, Influenza specific nasopharyngeal IgA and IgG on the left hand axis(expresscd . 
as raw ELISA data, Ab.490nm) and virus neutralisation activity of the nasal washes on 
the right hand axis(expressed as a neutralisation index (NI), asterisk sign).
Graph C, Serum IgA and IgG on the left hand axis (expressed as raw ELISA data, 
Ab.490nm) and serum haemagglutination activity on the right hand axis (expressed as a 
histogram, HI log]).
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Figure 5.3.11 Immunological responses of naive pony in response experimental
infection.
Data derived from a single pony: Pony V14
Figure 5.3.11 shows the nasopharyngeal and systemic antibody responses to an 
experimental infection.
^  = experimental challenge
- O  IgA > j<  VN IgG
Graph A, Influenza speciflc nasopharyngeal IgA and IgG on the left hand axis (expressed 
as arbitrary umts (AU), as a function of total isotype) in relation to circulating influenza 
specific ASC on the right hand axis (expressed as a histogram showing numbers of ASC 
/10^  PBMC).
□  IgG ASC H  IgA ASC
Graph B, Influenza specific nasopharyngeal IgA and IgG on the left hand axis(expressed 
as raw ELISA data, Ab.490nm) and virus neutralisation activity of the nasal washes on 
the right hand axis(expressed as a neutralisation index (NI), asterisk sign).
Graph C, Serum IgA and IgG on the left hand axis (expressed as raw ELISA data,
Ab.490nm) and serum haemagglutination activity on the right hand axis (expressed as a
histogram, HI log]).
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Figure 5.3.12 Immunological responses of a previously infected pony in response
experimental infection.
Data derived from a single pony: Pony A51
\ , •
Figure 5.3.12 shows the nasopharyngeal and systemic antibody responses to an
experimental infection.
^  = experimental challenge
- O  IgA >(c VN IgG
Graph A, Influenza specific nasopharyngeal IgA and IgG on the left hand axis (expressed 
as arbitrary units (AU), as a ftmction of total isotype) in relation to circulating influenza 
specific ASC on the right hand axis (expressed as a histogram showing numbers of ASC
/lO^PBMC).
□  IgG ASC g  IgA ASC
Graph B, Influenza specific nasopharyngeal IgA and IgG on the left hand axis(expressed 
as raw ELISA data, Ab.490nm) and virus neutralisation activity of the nasal washes on 
the right hand axis(expressed as a neutralisation index (NI), asterisk sign).
Graph C, Serum IgA and IgG on the left hand axis (expressed as raw ELISA data, 
Ab.490nm) and serum haemagglutination activity on the right hand axis (expressed as a 
histogram, HI log]).
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Figure 5.3.13 Immunological responses of a previously infected pony in response
experimental infection.
Data derived from a single pony: Pony 40A
Figure 5.3.13 shows the nasopharyngeal and systemic antibody responses to an 
experimental infection.
^  = ejqjerimental challenge
-O- IgA >}( VN IgG
Graph A, Influenza specific nasopharyngeal IgA and IgG on the left hand axis (expressed 
as arbitrary units (AU), as a ftmction of total isotype) in relation to circulatihg influenza 
specific ASC on the right hand axis (expressed as a histogram showing numbers of ASC 
/10  ^PBMC).
. . □  IgGASC g  IgA ASC
Graph B, Influenza specific nasopliaryngeal IgA and IgG on the left hand axis(expressed 
as raw ELISA data, Ab.490nm) and virus neutralisation activity of the nasal washes on 
the right hand axis(expressed as a neutralisation index (NI), asterisk sign).
Graph C, Serum IgA and IgG on the left hand axis (expressed as raw ELISA data, 
Ab.490nm) and serum haemagglutination activity on the right hand axis (expressed as a 
histogram, HI log2).
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Figure 5.3.14 Nasal shedding of influenza virus after experimental challenge
Figure 5.3.14 shows influenza virus nucleoprotein as detected by ELISA (Ab.470nm) and 
virus isolation in fertile hens eggs (TCID50). Graph A shows data from the negative 
control ponies (V4, V7, V9, and VI4). Graph B shows data fix)m the intranasally 
vaccinated ponies (F79, 90F, 1669,6431, 04B, C4D), and graph C showing the positive 
controls (A51 and 40A) which had been infected six months previously.
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5.3.4 Summary of results
The table below (5.4.1) summarises the data for antibody and antibody secreting cells 
(ASC) at the time of infection, and the clinical/virological outcome of experimental 
challenge. Vaccinated ponies were F79,90F, 1669, 6431, 04B, C4D, previously infected 
ponies were A51 and 40A, and unvaccinated control ponies were V4, V7, V9, V14.
Table 5.4.1 Summary of immunological and virological results
Pony Vac. Post Vaccination Post infection Infect
(VI)
(inf.) IgA
ASC
IgG
ASC
Virus
Neut
(NI)
HI
flog2)
IgA
ASC
(Day)
IgG
ASC
(Day)
Virus
Neut
(NI)
HI
Gog2)
¥19 23 24 3.18 8 1 3 5.43 8 %(-)
90F ✓ 25 18 2.43 9 1 5 2.81 9 x (-)
1669 y 47 30 4.06 10 2 5 5.43 10 x (-)
6431 y 7 12 1.06 7 2 2 2.31 7 %(-)
04B y 10 2 0 2.31 8 0 3 2 .6 8 8 / ( - )
C4D y 6 25 0 .6 8 6 0 1 1.43 6 %(-)
A51 inf. ND ND 0.81 5 7 18 1.18 5 %(-)
40A inf. ND ND 0.81 5 4 5 1.18 6 X(-)
V4 X ND ND 0.18 < 2 6 5 1.31 5 y (+ )
V7 X ND ND 0.18 < 2 2 3 1.43 6 y (+ )
V9 X ND ND 0.18 < 2 10 11 1.43 6 y (+ )
V14 X ND ND 0.18 < 2 3 4 1.43 7 y (+ )
footnotes:
Vac. = vaccinated i.n.(y), negative control (X ), or positive control which has been infected 
previously (inf.)
Post Vaccination = Serological assays (NI and HI) assayed time point 2 days prior to challenge, 
ASC data was measured at various time points after the final intranasal boosting vaccination (data 
presented corresponds to the peak response observed amongst these time points).
Post Infection = Serological assays (NI and HI) assayed at a time point 14 days after infection, 
ASC data was measured at various time points after infection (data presented corresponds to the 
peak response observed amongst these time points).
IgA ASC and IgGASC = Peak influenza specific ASC responses / 10^  PBMC.
A7=Neutralisation index of influenza virus growth of the nasal washes.
HI= Haemagluttination inhibition titre of serum (log2).
ND = Not done.
Infect (VI) = Animal was infected: yes ( / )  or no (X ) and virus was isolated from nasal swabs 
(VI): yes (+) or no (-).
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The results presented above will be discussed fully in the Discussion section of this
chapter (5.4), however, some prima facie observations may be drawn from the
summarised data.
• All animals that had been vaccinated with the intramuscular prime/intranasal boost 
regime were protected from experimental infection.
• The virological outcome of the experimental infection in the vaccinated animal and the 
positive control group (A51 and 40A) was identical in that no virus could be detected 
in nasal swabs after infection.
• The serum HI titre in the vaccinated animal group was of a protective level prior to 
infection (>5 log2), this titre did not increase after infection.
• The level of nasal wash virus neutralisation activity in the samples taken from the 
vaccinated ponies before infection was greater that that seen in the nasal washes taken 
from the negative control ponies after infection (in 5 out of the 6  ponies).
• High levels of nasal wash virus neutralisation activity were not required to protect the 
positive control ponies from infection (A51 and 40A).
5.4 Discussion
Studies with conventional inactivated equine influenza vaccines have shown that 
protection from experimental infection is strongly correlated with the level of circulating 
antibody to haemagglutinin (Mumford et al., 1983,1988) and that after an influenza 
infection, clinical immunity in horses may last as long as 62 weeks (Hannant et al., 
1988b). This immunity, in contrast to the situation observed after vaccination, can be 
shown in animals with no detectable circulating influenza-specific antibody. Influenza- 
specific antibodies have also been detected in the mucosal secretions after an infection 
(Hannant et al., 1988a, 1989a) and may be recalled very rapidly after new exposure 
(Hannant et al., 1989a).
The studies described here with inactivated influenza antigens and CTB showed that in 
contrast with conventional systemic vaccines, intranasal vaccination of systemically 
primed ponies stimulates not only systemic antibody responses but also functional 
mucosal antibody responses, as measured by haemagglutination inhibition and virus 
neutralisation assays. Virus neutralising IgA occurs after natural infection and has been
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implicated to be the major correlate of homo- and heterotypic immunity to influenza virus 
in other animals (Liew et al., 1984; Asanuma et al., 1995). The mucosal and systemic 
antibody responses induced in horses by influenza/CTB vaccination are very similar to 
those seen after equine influenza infection. However, currently there is no evidence for 
cellular immune responses induced by this type of mucosal vaccination of horses.
The intranasal vaccination of systemically primed horses with CTB and S89 induced 
sufficient mucosal virus neutralising IgA and systemic HI antibody to confer protection 
from experimental influenza infection (see 5.3.3.1). It is hypothesised that the success of 
the intranasal vaccination and ultimately protection from infection was dependent on 
systemic priming with influenza virus antigen. This statement is speculative as no 
controlled experiment was performed in which naive ponies were vaccinated with the 
nasopharyngeal applicator and a vaccine to which 2 % holotoxin had been added; however 
it is in accord with some previously published studies (Barzu et al., 1996). One can only 
speculate as to the reason behind this requirement for systemic priming, possibly the 
induction of naive T-cells to become memory T-cells may not be adaquate within the local 
lymph node because of the unsuitable local cytokine environment or APC function. These 
features require further investigation.
It has been shown that animals vaccinated systemically with particular vaccine antigens 
may be protected clinically from heterotypic infection. However, these animals may still 
shed large amounts of live virus from their nasopharynx in the absence of clinical signs 
(Mumford et al., 1997). For example. Equine influenza vaccines derived from North 
American influenza strains induced clinical protection when challenged with European 
strains of virus, however, these ponies shed significantly more live virus than the control 
ponies which had been vaccinated with influenza vaccines comprising European influenza 
virus strains (Mumford et al., 1997). No speculation can be made as to the relative 
contribution of intranasal vaccine-induced mucosal antibody in protection from infection 
because of the high level of background circulating antibody which was also induced. This
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HI antibody in all of the vaccinated ponies was of sufficient magnitude to confer 
protection in the absence of mucosal immunity. Mucosal influenza specific IgA has been 
implicated in heterotypic protection (Liew et al., 1984; Asanuma et al., 1995), and may 
therefore significantly improve protection from newly emergent or "foreign" viruses. 
Therefore, the advantages of mucosal vaccination may only be highlighted at a later date 
when experimental infections with heterotypic influenza virus are performed.
Influenza specific ASC were observed in the PBMC very rapidly after intranasal boosting. 
This response mimics the rapid recall responses seen after a second influenza infection 
(Hannant et al., 1989a), and encourages the use of mucosal vaccination as an emergency 
measure to "blitz" vaccinate a stable yard in the face of an epidemic.
The inclusion of 2% CT holotoxin as a supplement to the vaccine mixture had a 
significant effect on the magnitude of the resultant immune response (p<0.05). The 
numbers of CTB specific IgG ASC in the PBMC of vaccinated animals increased from a 
mean of 41 (mean ASC/10^ PBMC, n=3) in animals that recieved CTB alone (mean age 6  
months), to 258 (mean ASC/10  ^PBMC, n==6 ) in animals that recieved CTB plus 2% CT 
and influenza antigen, mean age 12 months). The control group described above is a 
composite group comprising animals which had been vaccinated using both the plastic 
pasteur pipette and the nasopharyngeal applicator. The effect of method of CTB 
administration on the resultant CTB specific ELISPOT responses was thought not to be 
significant, as previous experience showed no effect (n = 2 ).
These studies have shown conclusively that immunity may be induced in equids by 
intranas2d vaccination regimes containing inactivated virus antigens. CTB specific 
immunological responses could be induced by intranasal priming and intranasal boosting. 
However, in order for bystander antigen specific responses to occur (in this case influenza 
virus), systemic priming by conventional intramuscular vaccination or previous infection 
was necessary before intranasal boosting.
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Chapter 6
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Chapter 6 Discussion 
Summary o f findings
A fundamental requirement for the efficient functioning of a mucosal vaccine is a targeted 
vaccination procedure. The horse has well defined lymphoid areas within the nasopharynx 
which, because of its remote site, present problems of accessibility for vaccination. During 
this project I have developed an intranasal applicator, described in chapter 4. This 
apparatus allows a small quantity of vaccine to be delivered in a fine spray and coating a 
large area with vaccine, including all of the lymphoid structures. The nasopharyngeal 
applicator has also been utilised during the sampling of nasopharyngeal secretions. This 
improvement of an old technique has improved the reproducibility of the nasal washing 
procedure, in terms of reproducibility and overall yield.
Techniques have also been developed in order that data derived fit>m nasal wash samples 
could be interpreted more reliably. It became clear during the course of these 
developments that day to day variations of secretions, and sampling efficiency, would 
make interpretation of raw ELISA data very difficult. The changes that occur after events, 
such as a vaccination or infection, in the physicochemical quality of the nasal washes 
make it necessary to express the antigen specific ELISA data as a function of the total 
amount of isotype specific immunoglobulin present in the nasal wash.
We have demonstrated previously that mucosal vaccination, or natural infection (Hannant 
et al., 1988a and 1989a), can induce virus specific immunoglobulins in the nasal 
secretions in the horse. This study, however, has been the first to describe fimctional 
activity of those nasopharyngeal antibodies. The nasal washes taken after intranasal 
vaccination show haemagglutination inhibition and virus neutralisation (VN) activity in
140
tissue culture. The VN activity of the nasal washes correlated with the levels of virus 
specific IgA present in the nasal wash.
This study has been the first investigation of the mucosal immune system in the horse. It 
has made the first tentative confirmation, by the demonstration of trafficking B cells after 
mucosal vaccination, of the existence of a local mucosal immune system in the horse. It is 
proposed that the antigen specific IgA antibody secreting cells (ASC) are trafficking in a 
targeted manner to the mucosal lamina propria within the upper respiratory tract. The 
antigen specific IgG ASC do not migrate preferentially to mucosal sites such as the upper 
respiratory tract. However, it may be that the non-appearance of influenza specific IgG in 
the nasopharynx may purely be because of a lack of IgG transport from the LP into the 
airway lumen.
This thesis is the first description of a mucosal vaccine in the horse. The vaccine 
formulated with heat inactivated influenza antigen and cholera toxin B chain, was 
successful in inducing systemic and nasopharyngeal anti-influenza immune responses. 
These immunological responses were sufficient to protect horses fully from an 
experimental influenza infection. This study is one of very few that have been previously 
published (Israel et al., 1992; Hoshi et al., 1995) in which a mucosal vaccination confers 
protection from an important species specific pathogen within its natural host.
Future use and development o f mucosal vaccines
To achieve commercial success the vaccine of the future will have to fulfil several 
requirements for the modem world. Each vaccine will have to work with great efficacy, be 
easily and painlessly administered by non-professionally qualified personnel, and remain
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stable enough to survive long periods of transport. Veterinary vaccine manufacturers are 
already looking into the possibility of moving away from "needle" based vaccines, in 
order to make the inoculation itself more acceptable to both patient and owner (R. Jacobs, 
personal communication). Mucosal vaccines hold many advantages in a veterinary market. 
The ease of application and the possibility of mass vaccination, through water troughs or 
vaccine nebulised into the air, make it very attractive to veterinarians treating large 
numbers of communal animals. This approach may be less applicable to species like the 
horse when non-living vaccines are used which may require too high an antigen dose or 
too frequent boosting. As such, mucosal vaccines are receiving much attention from 
researchers and pharmaceutical company marketing departments alike.
No speculations have been made as to the relative contribution of mucosal antibodies to 
the protection of the ponies from experimental infection. Israel et al. (1992) attempted to 
address this question in cattle by electron microscopy on the epithelium of cattle 
challenged with bovine herpes virus-1 (BHV-1). This experiment demonstrated the failure 
of virions to bind onto and penetrate the epithelium of cattle which had been intranasally 
vaccinated with BHV-1 and CTB, and experimentally challenged with infectious BHV-1. 
The anti-influenza role of mucosal antibodies could be shown in the future, in a less 
invasive fashion, by the challenge of mucosally and systemically vaccinated groups with 
heterologous virus. With the putative benefits of mucosal antibody in the heterotypic 
protection of influenza virus, the mucosally vaccinated animals may be distinguishable 
from the systemically vaccinated ponies by virtue of the fact that a much reduced nasal 
shedding of live virus would be observed after experimental infection.
In general, very little is currently known about the interaction of antigen presenting cells 
(APC) and T-cells in the mucosal immune system. Still less is known about APC in the 
horse. Dendritic cells (DC) have been identified as major APCs in the mucosal immune
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system (Havenith et al., 1993; Holt et al., 1994; Xia et al., 1995), and have recently been 
the target of much research in the equid (Seidec et al., 1995). Investigations to define the 
role of DCs is therefore an interesting direction for future research to take. These 
experiments could include using antigen-pulsed DCs as experimental vaccines, and the 
use of efferent DCs after a mucosal vaccination to stimulate T-cell activity in vitro. Such 
experiments would confirm the role of DCs in the induction of a mucosal immune 
response and allow the construction of more intelligently designed vaccines.
The ELISPOT assay which has now been developed is a powerful tool for the 
investigation of immune responses. In other species, B-cells observed after a mucosal 
vaccination traffic to distant mucosal effector sites because of their expression of integrins 
that interact specifically with ligands expressed on endothelia at mucosal sites. In the 
human the integrin a4p7 expressed on the lymphocyte specifically binds to the 
MADCAM-1 molecule present on the high endothelial venule (HEV) of mucosal epithelia 
(Kilshaw and Murant, 1991; Hu ef al., 1992; Berlin et al., 1993; Erie et al., 1994; Hamann 
et al., 1994; Viney et al., 1996). The expression of such integrins and addressins should be 
investigated in the equid. If parallel systems can be established, any immune response to 
systemic or mucosal vaccination could be investigated. This approach would be useful if 
systemic routes of vaccination were to be developed in order to induce mucosal antibody 
(Daynes et al., 1996).
This thesis does not investigate the induction of antigen specific T-cell responses by 
mucosal vaccination. Recently, CTB combined with influenza virus nucleoprotein (NP) 
has been shown to induce cellular responses which have an important role in the clearance 
of virus from infected mice (Tamura et al., 1996). The intranasal vaccination of these 
mice with recombinant NP and CTB induced systemic delayed-type hypersensitivity 
(DTH) reactions, increased production of INF-y in response to virus in vitro, increased
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numbers of nasal CD4 +ve T-cells after challenge, but not NP-specific cytotoxic 
lymphocytes (CTL). Protection from other equine viruses, such as equine herpes virus-1 
(EHV-1), is thought to require a strong CTL response to infection. If CTB, as an adjuvant 
does not induce CTL responses, more intelligently designed vaccines which will induce 
endogenous presentation of antigen would therefore have to be investigated.
In the future it will be necessary to design each new mucosal vaccine in accordance with 
the identified correlates of immunity. Each disease will have to be treated individually 
according to the types of protective immune response involved. New adjuvants and 
delivery vectors, as well as DNA technology, need to be investigated in the horse. The use 
of vectors such as liposomes will allow great flexibility for the induction of mucosal 
immune responses. The particulate nature of liposomes will increase the uptake of antigen 
by cells such as DCs, while cytokines such as GM-CSF could be encapsulated and 
stimulate the DCs further to induce both cellular and humoral immunity. Liposomes can 
also be used to boost responses of peptide vaccines by better presentation of the peptide 
for endogenous processing. In this manner the vaccine could be further targeted, and 
designed in a manner which is optimal for each given pathogen.
Mucosal vaccination has great potential for use in the future. It may induce systemic 
immune responses at least as well as conventional vaccination, and also confers the 
advantages of mucosal immune responses. The putative requirement for systemic priming 
may not necessarily be a huge drawback in the human field, as an intranasal vaccine 
would be much more acceptable than repetitive needle based boosters. The advantages of 
mucosal vaccines might include mucosal virus neutralising antibodies and intraepithélial 
CTL, which together can prevent infection at the site of initial contact. This may be 
particularly important where pathogens quickly pass the epithelial bamer and set up 
immune suppression and latency.
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AM Alveolar Macrophage
APC Antigen Presenting Cell
ASC Antibody Secreting Cells
BAL Broncho-alveolar Lavage
BALT Bronchus Associated Lymphoid Tissue
BBS Borate Buffered Saline
BCIP 5-bromo-4-chloro-indolyl phosphate
BHV Bovine Herpes Virus
BSA Bovine Serum Albumin
cAMP Cyclic AMP
CMIS Common Mucosal Immune System
CT Cholera Toxin
CTA Cholera Toxin A chain
CTB Cholera Toxin B chain
CTL Cytotoxic T-Lymphocyte
DC Dendritic Cell
DTT Dithiothreitol
EHV Equine Herpes Virus
ELISA Enzyme-linked Immunosorbent Assay
ELISPOT Enzyme-linked Immunosorbent Spot forming assay
ESA Equine Serum Albumin
PCS : Fetal Calf Serum
GALT Gut Associated Lymphoid Tissue
Glut Glutaraldehyde
GMl Monosialoganglioside GMl
HA Haemagglutination
HAU Haemagglutination Unit
HEL Hen Egg Lysozyme
HEV High Endothelial Venule
HI Haemagglutination Inhibition
HSV Herpes Simplex Virus
lEL Intra-epithelial Lymphocyte
ISCOM Immune Stimulating Complex
LAK Lymphokine-activated Killer cell
LP Lamina Propria
LPL Lamina Propria Lymphocyte
LTB E.Coli heat-labile enterotoxin B sub-unit
MALT Mucosae Associated Lymphoid Tissue
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NK Natural Killer Cell
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Peripheral Blood Mononuclear Cells 
Phosphate Buffered Saline 
Polymeric Immunoglobulin Receptor 
Peyers’ Patch 
Respiratory Tract 
A/Equi/2/Sussex/89 Influenza 
Secretory IgA
Simian Immunodeficiency Virus
3 -(2-pyridyldithio) proprionic acid succinimide ester
T-Cell Receptor
T-helper class 1
T-helper class 2
Upper Respiratory Tract
Virus isolation
Virus neutralisation
Virus Transport Medium
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